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Abstract
We present a novel method for extracting cancer signatures by applying
statistical risk models (http://ssrn.com/abstract=2732453) from quantitative
finance to cancer genome data. Using 1389 whole genome sequenced samples
from 14 cancers, we identify an “overall” mode of somatic mutational noise.
We give a prescription for factoring out this noise and source code for fixing
the number of signatures. We apply nonnegative matrix factorization (NMF)
to genome data aggregated by cancer subtype and filtered using our method.
The resultant signatures have substantially lower variability than those from
unfiltered data. Also, the computational cost of signature extraction is cut by
about a factor of 10. We find 3 novel cancer signatures, including a liver cancer
dominant signature (96% contribution) and a renal cell carcinoma signature
(70% contribution). Our method accelerates finding new cancer signatures
and improves their overall stability. Reciprocally, the methods for extracting
cancer signatures could have interesting applications in quantitative finance.
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1 Introduction and Summary
One in eight human deaths is caused by cancer. Cancer stands out among diseases
for it stems from somatic alterations in the genome. One common type of somatic
alterations found in cancer is due to single nucleotide variations (SNVs) or alter-
ations to single bases in the genome. These SNVs are accumulated throughout the
lifetime of the cancer via exposures to different mutational processes. These pro-
cesses can be endogenous to the cell such as imperfect DNA replication during cell
division or spontaneous cytosine deamination [Goodman and Fygenson, 1998], [Lin-
dahl, 1993]. They can also be exogenous due to exposures to chemical insults or
ultraviolet radiation [Loeb and Harris, 2008], [Ananthaswamy and Pierceall, 1990].
All of these mutational processes, whether extrinsic or intrinsic, will leave evidence
of their activity in the cancer genome characterized by distinctive alteration pat-
terns or mutational signatures. From a knowledge standpoint, if one can identify all
signatures and thus all mutational processes contributing to cancer, then one can
begin to understand the origins of cancer and its development. From a therapeutic
point of view, if there are no discernible patterns of mutations between different
cancer types, then different cancers will mostly likely require their own type-specific
or even patient-specific therapeutics. However, if there is a much smaller number of
mutational signatures describing all or most cancer types, then a therapeutic for one
cancer type with certain mutational signatures present may very well be applicable
across other cancer types with the same or similar mutational signatures.4
At present, the identification of mutational signatures involves analyzing SNV
patterns present in a cohort of DNA sequenced whole cancer genomes. SNVs found
in each cancer genome can be classified into 96 distinct mutation categories.5 The
data is organized into a matrix Gis, where the rows correspond to the N = 96
mutation categories, the columns correspond to d samples, and each element is a
nonnegative occurrence count of a given mutation in a given sample. The commonly
accepted method for extracting cancer signatures from Gis [Alexandrov et al, 2013a]
is via nonnegative matrix factorization (NMF) [Paatero and Tapper, 1994], [Lee and
Seung, 1999]. Under NMF the matrix G is approximated via G ≈ W H, where WiA
is an N×K matrix, HAs is a K×d matrix, and both W and H are nonnegative. The
appeal of NMF is its biologic interpretation whereby the K columns of the matrix
W are interpreted as the weights with which the K cancer signatures contribute into
the N = 96 mutation categories, and the columns of the matrix H are interpreted
4 Another practical motivation for identifying cancer signatures is prevention, by pairing the
signatures observed in cancer samples with those caused by exposure to various carcinogens.
5 In brief, DNA is a double helix of two strands, and each strand is a string of letters A, C,
G, T corresponding to adenine, cytosine, guanine and thymine, respectively. In the double helix,
A in one strand always binds with T in the other, and G always binds with C. This is known
as base complementarity. Thus, there are six possible base mutations C > A, C > G, C > G,
T > A, T > C, T > G, whereas the other six base mutations are equivalent to these by base
complementarity. Each of these 6 possible base mutations is flanked by 4 possible bases on each
side thereby producing 4× 6× 4 = 96 distinct mutation categories.
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as the exposures to the K signatures in each sample. The price to pay for this is
that NMF, which is an iterative procedure, is computationally costly and depending
on the number of samples d it can take days or even weeks to run it. Furthermore,
it does not automatically fix the number of signatures K, which must either be
guessed or obtained via trial and error, thereby adding to the computational cost.
Additional considerations include: i) out-of-sample instability, i.e., the signatures
obtained from non-overlapping sets of samples can be dramatically different; ii) in-
sample instability, i.e., the signatures can have a strong dependence on the initial
iteration choice; and iii) samples with low counts or sparsely populated samples
(i.e., those with many zeros – such samples are ubiquitous, e.g., in exome data) are
usually deemed not too useful as they contribute to the in-sample instability.
Happily, a conceptually similar problem is well-studied in quantitative finance
and we can simply borrow from the arsenal of tools developed there once we establish
a dictionary between the biologic and finance quantities. Thus, in the quant finance
context one deals with a portfolio of N stocks, which are analogous to the N = 96
mutation categories. The data consists of a time series of d (e.g., daily) stock returns
for each stock, so we have an N×d matrix Ris. The d observations in the time series
of stock returns are analogous to the d samples in the cancer data. The returns Ris
are analogous to the counts Gis except that the returns Ris need not be positive.
However, this does not affect what we wish to borrow from quantitative finance.
The sample correlation6 matrix Ψij computed based on the time series of stock re-
turns contains important information about the correlation structure of the returns.
Its spectral decomposition via principal components provides a tool for identify-
ing common risk factors underlying the returns, i.e., up to an error term, we have
R ≈ Ω F , where the columns of the N ×K (so-called factor loadings) matrix ΩiA
are related to the first K principal components of Ψij, and the columns of the K×d
matrix FAs are the time series of the factor returns. In our dictionary, the matrix
Ω is analogous to the matrix W , and the matrix F is analogous to the matrix H.
So, why is this useful, especially considering that the matrices Ω and F are not
nonnegative in the finance context? There are two pieces of useful information we
can extract from this analogy. First, algorithms for fixing the number of factors K
are readily available [Kakushadze and Yu, 2016b]. So, if we compute the sample cor-
relation matrix Ψij based on our occurrence count matrix Gis and apply the methods
employed in statistical risk models, we can fix the number of cancer signatures (or at
least a useful expected range for it) based on purely statistical methods.7 E.g., one
such method proposed in [Kakushadze and Yu, 2016b] is based on eRank (effective
rank) [Roy and Vetterli, 2007] of Ψij and appears to work well for cancer signatures.
Second, intuitively it is clear that there is a lot of noise in the occurrence count
data Gis. There are mutations that also occur in healthy humans, e.g., via imper-
fections in DNA repair. Furthermore, one can expect that in the presence of cancer
6 The sample covariance matrix Cij = σiσjΨij , where σ
2
i are the sample variances and Ψii ≡ 1.
7 We review these methods in detail below. The gist of the idea is to identify K which optimizes
the contributions from the factors (signatures) and the error terms into the diagonal of Ψij .
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such or similar mutations not directly associated with cancer signatures may become
more ubiquitous due to disruption in the normal operation of various processes (in-
cluding repair) in DNA. This “background noise” obscures the signatures and must
be identified and factored out of the data prior to attempting any signature ex-
traction. In the context of finance this is well-known as the “market” mode, which
corresponds to the overall movement of the broad market affecting all stocks (to
varying degrees) – cash inflow (outflow) into (from) the market tends to push stock
prices higher (lower). This is the market risk factor. To mitigate this risk factor,
one can, e.g., hold a dollar-neutral portfolio of stocks (the same dollar holdings for
long and short positions).8 And we can use this analogy for cancer signatures.
Based on our empirical analysis, we indeed find what we term the “overall” mode
– the analog of the “market” mode in finance – in the occurrence count data. It is
unequivocally present. Here is a simple way to understand this “overall” mode. The
average pair-wise correlation Ψij between different mutations (i 6= j) is nonzero and
is in fact high for most cancer types we study. This is noise that must be factored
out. If we aggregate samples by cancer type and compute the sample correlation
matrix Ψij for the so-aggregated data (across the n = 14 cancer types we study),
the average correlation is about 75% if we base it on Gis, and over whopping 96%
if we use the log-based matrix instead (see below). Another way of thinking about
this is that the occurrence counts in different samples are not normalized uniformly
across all samples. Therefore, running NMF on a vanilla matrix Gis could amount
to mixing apples with oranges thereby obscuring the true underlying signatures.
Factoring out the “overall” mode (or “de-noising” the matrix Gis) therefore most
simply would amount to cross-sectional (i.e., across the 96 mutation categories) de-
meaning. Simply put, we could demean the columns of Gis. One evident issue with
this is that, while the so-demeaned Gis can be used in the context of applying sta-
tistical factor model methods to it (recall that the returns Ris need not be positive)
to fix the number of signatures, we would not be able to run NMF on such a matrix
as it is no longer nonnegative. Another, more subtle issue is that distributions of
counts in Gis – the counts being nonnegative numbers – are not (quasi) normal but
skewed, with long tails at the higher end. In fact, they are quasi log-normal, which is
common for nonnegative quantities. Therefore, instead of demeaning the columns of
G, it makes much more sense to demean the columns of ln(G) (and re-exponentiate
for the purpose of running NMF). A minor hiccup is that some elements of Gis can
be 0. A simple way to deal with this is to set Ris = ln(1 + Gis) and construct the
correlation matrix Ψij based on Ris (as opposed to Gis) or R
′
is, which is Ris with
columns demeaned – this amounts to factoring out the “overall” mode. We run our
analysis using Ris, R
′
is as well as Gis and G
′
is (which is Gis with columns demeaned)
and unequivocally find that using “de-noised” log-based matrix R′is works best.
9
8 The “market” mode is the (quasi uniform) 1st principal component of Ψij : V
(1)
i ≈ 1/
√
N .
9 Table 1 summarizes the Mean/Median ratio and skewness for the matrices Gis and Ris across
cancer types and mutation categories and makes the skewed nature of the counts evident. This
skewness is exacerbated when we consider it across samples for many individual cancer types. Also,
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So, here is a simple prescription for fixing the number of signatures using our
statistical factor model based methodology. Compute R′is as above for the occur-
rence counts aggregated by cancer type. I.e., Gis is an N × n matrix, where the
number of cancer types n = 14 in our case. Compute the sample correlation matrix
Ψij based on R
′
is, i.e., the correlations are computed across the 14 cancer types.
Compute eRank(Ψij) and round it to the nearest integer. This is the expected num-
ber of cancer signatures K (excluding the “overall” mode, which is noise). This
simple procedure appears to work well for this purpose and we explain in detail
why this is the case based on the statistical factor model methodology, along with
another method for fixing K, which gives similar results. A complementary way
of fixing K is to compute the sample correlation matrices [Ψ(α)]ij for each cancer
type labeled by α = 1, . . . , n ([Ψ(α)]ij is computed based on the samples for the α-th
cancer type), take the first principal component [V (α)]
(1)
i for each correlation matrix
[Ψ(α)]ij, compute the n×n matrix of inner products E(1)αβ =
∑N
i=1[V (α)]
(1)
i [V (β)]
(1)
i ,
compute E1 = eRank(E
(1)
αβ ), and identify K with rounded E1. This method produces
essentially the same prediction for K as the aforesaid method using eRank(Ψij).
Once we fix the expected number of signatures K, we are ready to use NMF to
extract cancer signatures. However, as mentioned above, running NMF on Gis is
suboptimal as it contains noise due to the “overall” mode. A simple way to eliminate
the “overall” mode is to run NMF on the re-exponentiated matrix G˜is = exp(R
′
is).
Note that the elements in G˜is are no longer interpreted as “counts” – they are
fractional and low. We can include an overall normalization10 to make it look more
like the original matrix Gis, however, this does not affect the signatures extracted
via NMF.11 Now we are in good shape: we have the expected number of signatures
K and the “de-noised” matrix G˜is from which we can extract signatures via NMF.
Remarkably, what we find is 4 previously known signatures12 plus 3 new signa-
tures. One of the new signatures dominates liver cancer (with over 96% contribu-
tion), with almost no peak variability. Another new signature to a lesser degree
dominates renal cell carcinoma (with over 70% contribution). The third new signa-
ture appears mostly in bone cancer, brain lower grade glioma and medulloblastoma
(and also 5 other cancers to lesser degrees). We find the same signatures (plus the
“overall” mode) if we use Gis instead of G˜is, but the signatures are unequivocally
more stable when using G˜is. Simply put, removing the “overall” mode (the noise)
Figures 1 and 2 help visualize why factoring out the “overall” mode reduces noise.
10 E.g., we can take G˜is = exp(Mean(Ris) +R
′
is), or G˜is = exp(Median(Ris) +R
′
is), etc.
11 Technically speaking, after re-exponentiating we should subtract the extra 1 we added in the
definition Ris = ln(1+Gis). This can be done using the definitions in footnote 10 and the (relatively
scarce) negative elements resulting from subtracting 1 should be zeroed out. However, this does
not seem to affect the results much, so not to overcomplicate things we work with G˜is = exp(R
′
is).
12 To wit, mutational signatures 1 (spontaneous cytosine deamination), 2+13 (APOBEC medi-
ated cytosine deamination), 4 (tobacco carcinogen related exposure) and 17 (appearing in oesoph-
agus cancer, breast cancer, liver cancer, lung adenocarcinoma, B-cell lymphoma, stomach cancer
and melanoma; mutational process unknown) of [Nik-Zainal et al, 2012], [Alexandrov et al, 2013b].
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pays off high dividends. Now, we emphasize that our results are based on using
the occurrence counts aggregated by cancer type. The advantages of this method
include: i) the data is much less noisy than for samples by individual cancer type;
and ii) it allows us to use all genomic data, including that with low counts. In
this regard, our approach here can be readily applied to exome data, which we will
report elsewhere along with extending our analysis to individual cancer types.
The remainder of this paper is organized as follows. In Sections 2-4 we review the
quantitative finance machinery we borrow from. Section 5 applies this machinery to
cancer signatures. Section 6 discusses empirical results based on the published data
for the 14 cancer types. Section 7 discusses our NMF results. We briefly conclude
in Section 8. Appendix A lists the genome data sample IDs we use. Appendix B
contains our R source code for factor models. Appendix C contains some legalese.
2 Sample Covariance Matrix
2.1 Sample Data
In many practical applications we have N objects characterized by an observable
quantity, which is measured over d observations for each object. The resulting
data is an N × d matrix – call it Ris – where the rows correspond to the objects
labeled by i = 1, . . . , N , and the columns correspond to the observations labeled by
s = 1, . . . , d. In general there can be some missing observations, i.e., NAs in Ris.
However, for our purposes here it will suffice to assume that there are no NAs.
Here are some examples of such data. In finance we have N stocks, d trading
days,13 and we measure daily stock returns14 Ris. Or, e.g., i labels large cities in
the US (or, alternatively, zip codes), s labels years, and Ris is violent crime rate per
capita. In the context of this paper, we have N = 96 mutation types15 occurring in
various types of cancers, d is the number of collected samples, and Ris is (related to
– see below) the occurrence count for the mutation type i in the sample s.
2.2 Serial Covariances and Correlations
We can think of the matrix Ris as N series of d = M + 1 observations.
16 The
sample covariance matrix (SCM) is defined as an N ×N matrix of pair-wise serial
13 A trading day refers to a day on which the stock market is open.
14 E.g., the so-called close-to-close return, i.e., the return from yesterday’s closing price to today’s
closing price. This return can be defined as Ris = Pis/Pi,(s+1) − 1 or Ris = ln(Pis/Pi,(s+1)) (for
daily returns, usually |Ris|  1, so the difference between the two definitions is mostly small). A
further detail is that the closing prices Pis, Pi,(s+1) are fully adjusted for any splits and dividends.
15 We use “mutation type” and “mutation category” interchangeably.
16 In our finance example above, s labels dates in the N time series. More generally, the rows
of Ris are not necessarily time series. E.g., in the context of cancer mutations, we are dealing with
series of samples (without any reference to time or chronology). In what follows we will use the
adjective “serial” in the general context (be it dates, samples, etc.), not necessarily for time series.
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covariances:17
Cij =
1
M
M+1∑
s=1
Xis Xjs (1)
where Xis = Ris − Ri are serially demeaned quantities: Ri = 1M+1
∑M+1
s=1 Ris. SCM
contains important information about the quantity characterizing our N objects,
to wit: i) serial variances Cii = σ
2
i , which measure serial variability; and ii) serial
pair-wise correlations Ψij between different series (i 6= j). Here
Ψij =
1
σiσj
Cij =
1
M
M+1∑
s=1
Yis Yjs (2)
is the sample correlation matrix, and Yis = Xis/σi. Note that Ψii ≡ 1.
When M < N , Cij is singular: we have
∑M+1
s=1 Xis = 0, so only M columns of
the matrix Xis are linearly independent. Let us eliminate the last column: Xi,M+1 =
−∑Ms=1Xis. Then we can express Cij via the first M columns:
Cij =
M∑
s,s′=1
Xis φss′ Xjs′ (3)
Here φss′ = (δss′ + usus′) /M is a nonsingular M × M matrix (s, s′ = 1, . . . ,M);
us ≡ 1 is a unit M -vector. Note that φss′ is a 1-factor model (see below). Similarly,
Ψij =
M∑
s,s′=1
Yis φss′ Yjs′ (4)
2.3 Out-of-sample (In)stability
Suppose we compute SCM based on a set – call it set A – of d observations. Suppose
now we compute SCM based on a different set – call it set B – of d observations
such that set A and set B are non-overlapping. Typically, unless M  N , the
off-diagonal elements of SCM in the two computations can be vastly different. This
is known as out-of-sample instability of sample correlations.18 On the other hand,
sample variances tend to be much more stable out-of-sample and in many cases can
be reliably computed even if M  N . One way to think about this is to note that
Cii =
1
M
∑M+1
s=1 X
2
is, so if the serially demeaned quantities Xis are (quasi-)normally
distributed within each series and M  1, then Cii should be relatively stable.
17 The overall normalization of Cij , i.e., M (unbiased estimate) vs. M + 1 (maximum likelihood
estimate) in the denominator in (1), is immaterial for our purposes here. In many cases M  1.
18 This statement is often regarded as stemming from empirical evidence. However, it is well-
understood theoretically. We can always rotate our serially demeaned returns Xis to an orthogonal
basis and rescale them to have unit serial variances. Then the true covariance matrix is the N ×N
identity matrix. Pursuant to the Bai-Yin theorem [Bai and Yin, 1993], the smallest and largest
eigenvalues of SCM have the limits λmin = (1 −√y)2 and λmax = (1 +√y)2, where y = N/M is
fixed and N,M →∞. So for M,N  1 we must have M  N for all eigenvalues to be close to 1.
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2.4 Correlations, Not Covariances
In many applications involving SCM, it must be invertible and, furthermore, out-
of-sample stable.19 As mentioned above, in many cases SCM does not satisfy these
requirements and one replaces it with a constructed matrix such that it is positive
definite and more stable. However, in practice it is convenient to model the sample
correlation matrix Ψij instead of Cij, for two reasons. First, since sample variances
Cii are relatively stable and can be readily computed, there is no need to model
them; it is the pair-wise correlations Ψij (i 6= j) that require modeling. Second, in
many cases, the sample variances Cii have a skewed cross-sectional
20 (e.g., (quasi)
log-normal) distribution, as is often the case with positive-valued quantities. It is
therefore convenient to factor σi out of SCM, i.e., to work with the sample correlation
matrix Ψij = Cij/σiσj. Its diagonal elements are nicely uniform (Ψii ≡ 1), and the
off-diagonal elements Ψij (i 6= j) take values in (−1, 1) with a tight distribution.
We can think of Ψij as a sample covariance matrix for normalized quantities R˜is =
Ris/σi, i.e., Ψij = Cov(R˜i, R˜j) = Cor(Ri, Rj). So, in what follows we will always
work with Ψij and R˜is, and SCM will refer to the sample correlation matrix Ψij.
3 Factor Models
Factor models are a popular method for constructing a nonsingular replacement Γij
for Ψij:
Γij = ξ
2
i δij +
K∑
A,B=1
ΩiA ΦAB ΩjB (5)
Here: ξ2i is the specific (a.k.a. idiosyncratic) variance; ΩiA is anN×K factor loadings
matrix; and ΦAB is a K × K factor covariance matrix (FCM), A,B = 1, . . . , K.
The number of factors K  N to have FCM more stable than SCM. I.e., the off-
diagonal elements of SCM (i.e., the pair-wise correlations Ψij, i 6= j) are modeled via
contributions from K factors fAs, while the diagonal elements of SCM (i.e., Ψii ≡ 1)
receive contributions from the factors and purely diagonal specific variances ξ2i . This
corresponds to modeling R˜is via a matrix Υis such that:
Υis = χis +
K∑
A=1
ΩiA fAs (6)
Cov(χi, χj) = ξ
2
i δij (7)
Cov(χi, fA) = 0 (8)
Cov(fA, fB) = ΦAB (9)
Cov(Υi,Υj) = Γij (10)
19 This is required, e.g., in finance, in the context of stock portfolio optimization including
mean-variance optimization [Markowitz, 1952], Sharpe ratio maximization [Sharpe, 1994], etc.
20 Throughout herein “cross-sectional” refers to “across the index i”.
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As above, Cov(·, ·) are serial covariances.21 A nice feature of Γij is that it is positive-
definite (and thus invertible) if FCM is positive-definite assuming that all ξ2i > 0.
We can think about (6) as an approximation for the decomposition
R˜is = εis +
K∑
A=1
ΩiA fAs (11)
whereby R˜is, an N × d matrix, is assumed to essentially be described by a linear
K-factor model, fAs being the factors. Then εis corresponds to the “error” term, i.e.,
deviation from a linear factor model. Note that generally εis 6= χis. Thus, generally
the matrix Cov(εi, εj) is not diagonal, nor do the covariances Cov(εi, fA) vanish.
However, approximating R˜is via Υis is useful because constructing the factor model
(5) for SCM involves defining ΩiA, which we then can use to further compute the
factors fAs, e.g., via the least-squares method, i.e., by minimizing the “quadratic
error”
∑N
i=1 ε
2
is → min. This, by definition, is equivalent to a cross-sectional lin-
ear regression of R˜is over ΩiA (without the intercept), where fis are the regression
coefficients, whereas εis are the regression residuals.
22 So, we need to construct Γij.
3.1 “Binary” and “Analog” Factors
To construct a factor model, we need to define the factor loadings ΩiA. In the
context of the decomposition (11), the columns of ΩiA are nothing butK explanatory
variables. The question is how to pick them. And this is not a rhetorical question.
Thus, imagine that we can classify our N objects via a binary taxonomy, i.e., each
object belongs to one and only one “cluster”. This might be possible if the objects
can be grouped into “clusters” based on some similarity criteria. E.g., in the case
of stocks, they can be grouped into sectors, industries, sub-industries, etc. If such
a grouping is possible, then we can take our explanatory variables as ΩiA = δS(i),A,
where S maps our N objects into K “clusters”: S : {1, . . . , N} → {1, . . . , K}. I.e.,
ΩiA = 1 if the object labeled by i belongs to the “cluster” labeled by A; otherwise,
ΩiA = 0. These “binary” factors are based on the objects’ membership in “clusters”.
If a binary classification is not attainable, then we can try to use some measured
or estimated properties of our objects to populate the columns of our factor loadings.
We can refer to them as “analog” factors as they typically lack any “binary” or
“clustering” structure and characterize the entire cross-section of the N objects.
E.g., in the case of stocks such “analog” factors can be based on the companies’ size
(market capitalization), earnings, book value, etc.23 Even if some “analog” factors
can be defined, they may not always be good explanatory variables [Kakushadze
and Yu, 2016a], so care is in order when attempting to use them as columns in ΩiA.
21 For notational convenience we omit the index s in serial covariances Cov(·, ·).
22 For general ΩiA there are subtleties that require nontrivial modifications of the regression –
see [Kakushadze and Yu, 2016a] for details. For our purposes here such subtleties do not arise.
23 In the case of stocks such “analog” factors are called “style factors”.
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3.2 Statistical Factor Models
In many applications “binary” and “analog” factors mentioned above are unattain-
able or unreliable. In this case, we can resort to statistical factor models [Kakushadze
and Yu, 2016b]. The idea is simple. We have our data R˜is. What if we construct
ΩiA based on this data and no other input? I.e., we have to take an N × d matrix
and somehow distill it down to a smaller N ×K matrix. The question is how and
what should K be? And this is precisely where the factor model approximation via
Γij defined in (5) for the sample correlation matrix Ψij becomes a useful tool.
The idea behind statistical factor models is simple. Let V
(a)
i , a = 1, . . . , N , be
the principal components of Ψij forming an orthonormal basis
N∑
j=1
Ψij V
(a)
j = λ
(a) V
(a)
i (12)
N∑
i=1
V
(a)
i V
(b)
i = δab (13)
such that the eigenvalues λ(a) are ordered decreasingly: λ(1) > λ(2) > . . . . More pre-
cisely, some eigenvalues may be degenerate. For generic (large enough) datasets –
and this is not critical in what follows – the positive eigenvalues are non-degenerate.
However, we can have multiple null eigenvalues. Typically, the number of nonvan-
ishing eigenvalues24 is M , where, as above, d = M + 1 is the number of observations
in each series. So, we have (assuming M < N ; otherwise M is replaced by N below):
Ψij =
M∑
a=1
V
(a)
i λ
(a) V
(a)
j (14)
This resembles a factor model (5) with a diagonal factor covariance matrix. However,
the specific variance is missing. This can be rectified by noting that higher principal
components contribute in (14) with smaller weights, that is, eigenvalues. So, we
can simply keep only the first K principal components in the sum in (14), where
K < M , and replace the diagonal contribution of the droppedM−K higher principal
components via the specific variance:
Γij = ξ
2
i δij +
K∑
A=1
λ(A) V
(A)
i V
(A)
j (15)
ξ2i = 1−
K∑
A=1
λ(A)
(
V
(A)
i
)2
(16)
24 This number can be smaller if some series R˜is are 100% pair-wise (anti-)correlated. Again,
for generic datasets – and this not critical here – this is not the case.
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This corresponds to taking the factor loadings matrix and factor covariance matrix
of the form
ΩiA =
√
λ(A) V
(A)
i , A = 1, . . . , K (17)
ΦAB = δAB (18)
This construction is nicely simple. However, what should K be? Two simple meth-
ods for fixing K are discussed in [Kakushadze and Yu, 2016b], where R source code
for constructing statistical factor models is also given. We briefly review them here.
4 Fixing Factor Number
When K = M we have Γij = Ψij (which is singular if M < N). Therefore, we
must have K ≤ Kmax < M . So, what is Kmax? And what is Kmin (other than the
evident Kmin = 1)? It might be tempting to do complicated and convoluted things.
We will not do this here. Instead, we will follow a pragmatic approach. One simple
(“minimization” based) algorithm was set forth in [Kakushadze, 2015]. We review it
below and then give yet another simple algorithm based on eRank (effective rank).
4.1 “Minimization” Algorithm
The idea is simple [Kakushadze, 2015]. It is based on the observation that, as K
approaches M , min(ξ2i ) goes to 0 (i.e., less and less of the total variance Γii ≡ 1
is attributed to the specific variance, and more and more of it is attributed to the
factors), while as K approaches 0, max(ξ2i ) goes to 1 (i.e., less and less of the total
variance is attributed to the factors, and more and more of it is attributed to the
specific variance). So, we can define K as follows:
|g(K)− 1| → min (19)
g(K) =
√
min(ξ2i ) +
√
max(ξ2i ) (20)
This simple algorithm works well in practical finance applications, see [Kakushadze,
2015], [Kakushadze and Yu, 2016b]. Open source R code for computing statisti-
cal factor models (15) utilizing this “minimization” based algorithm for fixing the
number of factors K is given in Appendix A of [Kakushadze and Yu, 2016b].
4.2 Effective Rank
Another simple method is to set [Kakushadze and Yu, 2016b]25
K = Round(eRank(Ψ)) (21)
25 Here Round(·) can be replaced by floor(·) = b·c.
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Here eRank(Z) is the effective rank [Roy and Vetterli, 2007] of a symmetric semi-
positive-definite (which suffices for our purposes here) matrix Z. It is defined as
eRank(Z) = exp(H) (22)
H = −
L∑
a=1
pa ln(pa) (23)
pa =
λ(a)∑L
b=1 λ
(b)
(24)
where λ(a) are the L positive eigenvalues of Z, and H has the meaning of the (Shan-
non a.k.a. spectral) entropy [Campbell, 1960], [Yang et al, 2005].
The meaning of eRank(Z) is that it is a measure of the effective dimensionality
of the matrix Z, which is not necessarily the same as the number L of its positive
eigenvalues, but often is lower. This is due to the fact that many series Ris can be
highly correlated (which manifests itself by a large gap in the eigenvalues – see below)
thereby further reducing the effective dimensionality of the correlation matrix.
4.3 A Variation
When the average correlation26 Ψ = 1
N2
∑N
i,j=1 Ψij is high, then both the “minimiza-
tion” and eRank based algorithms can produce low values of K (including 1). This
is because in this case λ(1)  1 and there is a large gap between the first and higher
eigenvalues. To circumvent this, we can define K = K ′ + 1, where K ′ is defined as
above via the “minimization” or eRank based algorithms for the matrix
Ψ′ij =
M∑
a=2
V
(a)
i λ
(a) V
(a)
j (25)
I.e., we simply drop the first eigenpair, determine the corresponding value of K ′,
and add 1 to it. Open source R code for computing statistical factor models (15)
for both the “minimization” and eRank based algorithms with and without utilizing
the K ′ based definition is given in Appendix A of [Kakushadze and Yu, 2016b].
5 Application to Cancer Signatures
Now we are ready to apply the above machinery to cancer signatures. Our basic data
consists of a matrix – call it Gis – whose elements are occurrence counts of mutation
types labeled by i = 1, . . . , N = 96 in samples labeled by s = 1, . . . , d. More
precisely, we can work with one matrixGis which combines data from different cancer
types; or, alternatively, we may choose to work with individual matrices [G(α)]is,
26 Instead we can define Ψ = 1N(N−1)
∑N
i,j=1; i 6=j . Since N  1, the difference is immaterial.
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where: α = 1, . . . , n labels n different cancer types; as before, i = 1, . . . , N = 96; and
s = 1, . . . , d(α). Here d(α) is the number of samples for the cancer type labeled by
α. The combined matrix Gis is obtained simply by appending the matrices [G(α)]is
together column-wise. We will discuss a refinement of this data structure below.
The simplest thing we can do is to identify the matrix Ris in our discussion
above with Gis (or [G(α)]is).
27 However, this may not be the most optimal choice.
The issue is this. The elements of the matrix Gis are populated by nonnegative
occurrence counts. Nonnegative quantities with large numbers of samples tend to
have skewed distributions with long tails at higher values. I.e., such distributions
are not normal but (in many cases) roughly log-normal. One simple way to deal
with this is to identify Ris with a (natural) logarithm of Gis (instead of Gis itself).
A minor hiccup here is that some elements of Gis can be 0. We can do a lot of
complicated and even convoluted things to deal with this issue. Here we will follow
a pragmatic approach and do something simple instead – there is so much noise in
the data that doing otherwise simply does not pay off. So, we will simply take
Ris = ln (1 +Gis) (26)
This takes care of the Gis = 0 cases; for Gis  1 we have Ris ≈ ln(Gis), as desired.
Now we can construct statistical factor models for cancer signatures using the
“minimization” and eRank based methods (with or without the K ′ based variation)
for fixing the number of cancer signatures K. In fact, for the sake of completeness
and comparative purposes, below we will construct such factor models assuming
both (26) and Ris = Gis. Happily, qualitatively the results turn out to be similar.
6 Empirical Results
6.1 Data Summary
In our empirical analysis below we use genome data from published samples only.
This data is summarized in Table 2, where we give total counts, number of samples
and the data sources, which are as follows: A1 = [Alexandrov et al, 2013b], A2
= [Love et al, 2012], B1 = [Tirode et al, 2014], C1 = [Zhang et al, 2013], D1 = [Nik-
Zainal et al, 2012], E1 = [Puente et al, 2011], E2 = [Puente et al, 2015], F1 = [Cheng
et al, 2016], G1 = [Wang et al, 2014], H1 = [Sung et al, 2012], H2 = [Fujimoto et al,
2016], I1 = [Imielinksi et al, 2012], J1 = [Jones et al, 2012], K1 = [Patch et al, 2015],
L1 = [Waddell et al, 2015], M1 = [Gundem et al, 2015], N1 = [Scelo et al, 2014].
Sample IDs with the corresponding publication sources are given in Appendix A.
6.2 Genome Data Results
In our genome dataset we have 14 cancer types. Using the definition (26), we apply
the “minimization” and eRank based methods (with and without the K ′ based
27 The discussion below focuses on Gis and, unless stated otherwise, also applies to [G(α)]is.
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variation) for fixing the number of cancer signatures K. We use the R functions
bio.erank.pc() and bio.cov.pc() in Appendix B hereof, which are adapted from
Appendix A of [Kakushadze and Yu, 2016b]. The results are summarized in Table
3. Unless we use the K ′ based variation, the value of K tends to be low. If we
combine the samples from all 14 cancer types into a single “big” matrix (in our
case, of dimension 96× 1389), then we get K = 2 for the eRank based method and
K = 1 for the“minimization” based method (without the K ′ based variation). Both
of these methods produce K = 1 if we aggregate all samples within each cancer type
and run them on the resulting 96× 14 matrix. The question is, how come?
The answer is quite prosaic. Table 4 provides the average pair-wise correlation Ψ
(as defined in footnote 26) and the first 5 eigenvalues of the sample correlation matrix
Ψij. Except for Brain Lower Grade Glioma, Esophageal Cancer and Pancreatic
Cancer (for which cancer types the matrix Gis is sparsely populated with many 0s),
these average correlations are rather high and there is a large gap between the first
and higher eigenvalues. Therefore, the first eigenvector dominates in the spectral
decomposition (14). Excluding it via the K ′ based variation then produces higher
values of K. However, on general grounds we expect the higher principal components
to be out-of-sample unstable. That is, if we compute them based on two or more
sets of non-overlapping samples, there is no guarantee that they will be stable from
set to set. Therefore, we must address the issue out-of-sample stability first.
6.2.1 Out-of-sample (In)stability
A convenient way of addressing this issue is by checking whether the first and higher
principal components computed for each cancer type are stable from one cancer type
to another. As above, let [G(α)]is be the occurrence count matrix for the cancer type
labeled by α (for our genome data α takes 14 values). We then compute the corre-
sponding matrix [R(α)]is via (26) and the correlation matrix [Ψ(α)]ij. Let [V (α)]
(a)
i
be the a-th principal component of [Ψ(α)]ij. We then define a very informative
matrix of inner products
E
(a)
αβ =
N∑
i=1
[V (α)]
(a)
i [V (β)]
(a)
i (27)
By definition, E
(a)
αα ≡ 1, and |E(a)αβ | < 1 for α 6= β. This matrix can be thought of
as a measure of how “correlated” the a-th principal components are across different
cancer types. Table 5 gives summaries of |E(a)αβ | for a = 1, 2, 3 and α 6= β (there are
14 × 13 / 2 = 91 independent values for each a). For illustrative purposes, in the
fourth row we also give a summary of a similar matrix of inner products based on a
union of the second and third principal components. From Table 5 it is evident that
the first principal component is extremely stable from one cancer type to another.
However, higher principal components appear to be rather unstable. In this regard
it is informative to compute the eRank of the matrix E
(a)
αβ (using the calc.erank()
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subfunction in the bio.erank.pc() function in Appendix B hereof). For each a this
is a measure of how independent of each other the principal components [V (α)]
(a)
i are
across the 14 cancer types: the lower the eRank, the less independent they are, and
the more stable they are from one cancer type to another. So, for Ea = eRank(E
(a)
αβ )
we get E1 = 1.31, E2 = 9.49, E3 = 10.59, and E2+3 = 15.54, where E2+3 is based
on the union of the second and third principal components as above. Based on
the foregoing, it appears that higher principal components are highly out-of-sample
unstable. Put differently, higher (than the first) principal components computed for
one cancer type apparently have little predictive power for other cancer types.28
6.2.2 The “Overall” Mode
The first principal component is highly stable from one cancer type to another.
The values of E
(1)
αβ in Table 5 are mostly above 90%. This implies that we have a
dominant “overall” mode. In finance the analog of this is the so-called “market”
mode29 corresponding to the overall movement of the broad market, which affects
all stocks (to varying degrees) – cash inflow (outflow) into (from) the market tends
to push stock prices higher (lower). This is the market risk factor. To mitigate
this risk factor, one can, e.g., hold a dollar-neutral portfolio of stocks (i.e., the same
dollar holdings for long and short positions). And we can draw from this analogy.
We can think of the “overall” mode as follows. We can always write the sample
correlation matrix as
Ψij = (1− ρ) δij + ρ ui uj + ∆ij = Ψ′ij + ∆ij (28)
Here ρ = 1
N(N−1)
∑N
i,j=1; i 6=j Ψij is the average pair-wise correlation, ui ≡ 1 is the
unit N -vector, and
∑N
i,j=1 ∆ij = 0. In the zeroth approximation we can drop ∆ij,
i.e., Ψij ≈ Ψ′ij. Note that Ψ′ij is a 1-factor model. Its first principal component
U
(1)
i = ui/
√
N . It describes the “overall” mode, i.e., the average correlation of
all mutation types.30 This implies that in the zeroth approximation V
(1)
i ≈ U (1)i .
When N is large, in many systems this in fact is a good approximation. In our
case N = 96, so it is large enough. Table 6 gives cross-sectional summaries of
|√NV (1)i − 1| (assuming V (1)i are normalized such that
∑N
i=1 V
(1)
i > 0). It is evident
that V
(1)
i ≈ U (1)i is indeed a pretty good approximation and, not surprisingly, the
more total occurrence counts we have, the better this approximation works.
6.2.3 Factoring Out “Overall” Mode
The “overall” mode is clearly present and across all cancer types. Therefore it
makes sense to factor it out altogether before performing any analysis on the data.
28 To be clear, this does not mean that higher principal components are out-of-sample stable
within each cancer type. We will return to this issue below.
29 See, e.g., [Bouchaud and Potters, 2011] and references therein.
30 Note that the eigenvalue of Ψ′ij corresponding to U
(1)
i is λ
′
∗ = 1 + ρ (N − 1).
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Factoring out the “overall” mode is nothing but cross-sectionally demeaning the
matrix Ris, i.e., instead of Ris we use
R′is = Ris −Rs = Ris −
1
N
N∑
j=1
Rjs (29)
The results are given in Tables 7 and 8. The summary of the absolute values of pair-
wise inner products (in the units of 1%) between the first principal components of the
sample correlation matrices [Ψ(α)]ij for individual cancer types reads: Min = 0.122,
1st Qu. = 10.95, Median = 27.06, Mean = 30.83, 3rd Qu. = 42.86, Max = 90.74,
StDev = 22.89, MAD = 23.55, and E1 = 7.06. These results lead us to the following
nontrivial conclusion: there appear to be common signatures for these 14 cancer
types other than the “overall” mode. The value E1 = 7.06 suggests that the number
of these signatures K1 should be roughly 7. This is consistent with the values of K
in the last row of Table 7. However, Table 8 makes it clear that we no longer have a
large gap between the first and higher eigenvalues, so higher principal components
contribute substantially and it is difficult to expect out-of-sample stability.
6.2.4 No Log
Thus far we have been using the log-based definition (26). Let us now check what
transpires if we use the Ris = Gis definition. The results are given in Tables 9 and
10. Overall, the average correlations decrease and the values of K increase. The
summary of the absolute values of pair-wise inner products (in the units of 1%)
between the first principal components of the sample correlation matrices [Ψ(α)]ij
for individual cancer types reads: Min = 71.37, 1st Qu. = 83.86, Median = 96.53,
Mean = 92.05, 3rd Qu. = 97.95, Max = 99.59, StDev = 8.023, MAD = 2.934, and
E1 = 1.46. These results suggest that the log-based definition (26) does work better,
as we anticipated above based on the skewed nature of distributions of counts.
6.2.5 No Log with “Overall” Mode Factored Out
For the sake of completeness, let us also look at what happens if we use the Ris = Gis
definition and factor out the “overall” mode by cross-sectionally demeaning the so-
defined Ris. The results are given in Tables 11 and 12. The summary of the absolute
values of pair-wise inner products (in the units of 1%) between the first principal
components of the sample correlation matrices [Ψ(α)]ij for individual cancer types
reads: Min = 0.960, 1st Qu. = 31.80, Median = 44.93, Mean = 45.67, 3rd Qu. =
59.74, Max = 86.75, StDev = 20.57, MAD = 20.84, and E1 = 5.61. These results
show that with the no log definition we capture fewer independent signatures. This
should come as no surprise – the skewed nature of distributions of counts obscures
the underlying signatures. One way to see this is that for several cancer types sizable
average correlation is still present in Table 12 despite removing the “overall” mode.
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7 Nonnegative Matrix Factorization
7.1 First, A Multiplicative Model
Using the statistical factor model approach allows us to: i) fix the number of factors
K; and ii) remove the “overall” mode. The number of factors K1 excluding the
“overall” mode predicted by the eRank based method agrees with that obtained via
E1 in Subsection 6.2.3. However, a priori the statistical factor model approach would
appear to lack biologic interpretation. If we apply it directly to the no log definition
Ris = Gis (irrespective of the “overall” mode), the matrices ΩiA and FAs generally
can have negative elements. If we apply it to the log-based definition (26), then we
can re-exponentiate (11) via (recall that σ2i is the sample variance, and the factor
model is for the correlation matrix, which is why σi appears in the exponent)
31
Ĝis = exp
(
σiεis + σi
K∑
A=1
ΩiA FAs
)
= γis
K∏
A=1
(ZAs)
νiA (30)
where γis = exp (σiεis), ZAs = exp(FAs) and νiA = σiΩiA. So, ignoring the “multi-
plicative error” term γis for a moment, Ĝis provides a positive decomposition of the
matrix 1 + Gis, except that it is a multiplicative decomposition (as opposed to an
additive one, as in NMF). So, instead of “weights”, here we have the powers νis for
the “exposures” ZAs. In fact, such a multiplicative model may not be too farfetched.
The processes inside DNA do appear to have “exponential” tendencies. We intend
to discuss this approach in more detail in a forthcoming paper. Instead, here we
will apply the improvement we get from factoring out the “overall” mode to NMF.
7.2 NMF: Vanilla Counts Matrix
The commonly accepted method for extracting cancer signatures from Gis [Alexan-
drov et al, 2013a] is via nonnegative matrix factorization (NMF) [Paatero and Tap-
per, 1994], [Lee and Seung, 1999]. Under NMF the matrix G is approximated via
G ≈ W H, where WiA is an N ×K matrix, HAs is a K×d matrix, and both W and
H are nonnegative. The appeal of NMF is its biologic interpretation whereby the
K columns of the matrix W are interpreted as the weights with which the K cancer
signatures contribute into the N = 96 mutation categories, and the columns of the
matrix H are interpreted as the exposures to the K signatures in each sample.
Usually, NMF is applied either to individual cancer types or to a “big matrix”
obtained by combining the samples from all cancer types. Here we apply NMF in
a novel fashion to the 96 × 14 matrix obtained by aggregating samples by cancer
type. The advantage of this approach is that we get to include low count samples
31 Technically speaking, we should subtract the 1 we added inside the log in the definition (26).
Then we have to deal with negative values. This would obscure our discussion here with no benefit.
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without destabilizing the results (in-sample), and this way we also avoid undesirable
proliferation of signatures which can occur when the number of samples is large.32
We use organic R code for running NMF (and check that it produces the same re-
sults as the R package “NMF”, https://cran.r-project.org/package=NMF). We run
NMF for 100 “samplings” using random starting W and H for each “sampling”.33
Figure 3 gives the Pearson correlations between the vanilla matrix G and the re-
constructed matrix G∗ = W H for 5 to 9 signatures.34 The highest reconstruction
accuracy is achieved for K = 8 signatures, which is what we anticipated above for
the vanilla matrix (K1 = 7 plus the “overall” mode). Figures 4-11 plot the 8 sig-
natures. For each signature, the corresponding weights in the W columns (for each
of the 96 mutation categories) are averages over the 100 “samplings”, and the error
bars are the standard deviations.35 We discuss the interpretation of the signatures
below. Here we note that the error bars for the vanilla matrix are substantial. Also,
Signature 8 has substantial presence in most cancer types. This is the noise largely
stemming from the “overall” mode. Figure 12 summarizes signature contributions.
7.3 NMF: “Overall” Mode Factored Out
We now repeat the NMF procedure of the last subsection using the data with the
“overall” mode factored about. For this purpose, we simply re-exponentiate the
column-wise demeaned matrix R′is, i.e., we take
G˜is = exp(R
′
is) (31)
and run NMF on G˜is. We can include an overall normalization by taking G˜is =
exp(Mean(Ris)+R
′
is), or G˜is = exp(Median(Ris)+R
′
is), or G˜is = exp(Median(Rs)+
R′is) (recall that Rs is the vector of column means of Ris), etc., to make it look more
like the original matrix Gis, however, this does not affect the signatures extracted
via NMF.36 Again, technically speaking, after re-exponentiating we should subtract
the extra 1 we added in the definition (26) (assuming we include one of the aforesaid
overall normalizations). However, this does not seem to affect the results much.
Figure 13 gives the Pearson correlations between the vanilla matrix G˜ and the
reconstructed matrix G˜∗ = W H for 4 to 8 signatures. The highest reconstruction
accuracy is achieved for K1 = 7 signatures, which is what we anticipated above.
Figures 14-20 plot the 7 signatures, and the error bars are the standard deviations
for each mutation category as a result of the 100 “samplings”. Here we note that
the error bars for the “de-noised” matrix G˜ (Figures 14-20) are substantially smaller
than for the vanilla matrix G (Figures 4-11) due to factoring out the “overall” mode.
32 Such ubiquity of signatures generally makes them less useful.
33 Each “sampling” finds a local optimum – NMF does not guarantee global convergence.
34 This range is based on the values of K in the last rows of Tables 3 and 7.
35 We use the k-means clustering to sort the resultant signatures across the 100 “samplings”.
36 This is because each column of W , being weights, is normalized to add up to 1.
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Figure 21 summarizes signature contributions. Our Signatures 1-4 are previously
known signatures, to wit, mutational signatures 1 (spontaneous cytosine deamina-
tion), 2+13 (APOBEC mediated cytosine deamination),37 4 (tobacco carcinogen
related exposure) and 17 (appearing in oesophagus cancer, breast cancer, liver can-
cer, lung adenocarcinoma, B-cell lymphoma, stomach cancer and melanoma; mu-
tational process unknown) of [Nik-Zainal et al, 2012], [Alexandrov et al, 2013b].38
Our Signatures 5-7 are new. New Signature 5 dominates liver cancer (with over 96%
contribution), with almost no peak variability. New Signature 6 to a lesser degree
dominates renal cell carcinoma (with over 70% contribution). New Signature 7 ap-
pears mostly in bone cancer, brain lower grade glioma and medulloblastoma (and
also 5 other cancers to lesser degrees). The super-dominant liver cancer signature
is exciting. Tables 13 and 14 give weights with errors for the 7 signatures.
8 Concluding Remarks
• Out-of-sample (in)stability. This is a sticking point for any statistically based
method, which includes NMF. Usually, “stability” is addressed in the context of
NMF by perturbing the matrix G and checking whether the signatures are stable.
However, this does not address out-of-sample stability. Out-of-sample stability is
well-understood and is the bread-and-butter in the context of quantitative trading.
Since there one deals with time series and forecasting, if a given model lacks out-
of-sample stability, it is pretty much useless. This is because time flows only in one
direction and if a model built using parameters computed based on a time period in
the past does not perform well during a future time period – that is, out-of-sample
– it has no predictive (i.e., forecasting) power. In quantitative finance money is at
stake so methods for checking out-of-sample stability are rather well understood.
Based on those methods, a true test for out-of-sample stability in the context
of cancer signatures would be to take a set of samples, split it into 2 (or more)
non-overlapping subsets, independently extract signatures based on these subsets
and compare them. In fact, to have any kind of statistical significance, we would
need an ensemble of such non-overlapping sets. E.g., we could take some number
of samples and split them randomly into two halves a number of times. For this
to be meaningful, we need a sizable number of samples to begin with. The data
we work with in this paper is rather limited in this sense because it includes only
published genome samples. Not only is the number of cancer types limited to 14,
but the number of samples within each cancer type is also limited. E.g., for prostate
cancer we have mere 5 samples and any meaningful out-of-sample stability test for
that cancer type is unattainable. On the other hand, for liver cancer we have a
37 This was reported as a single signature (almost identical to our Signature 2) in [Alexandrov
et al, 2013b], however, subsequently, it was split into 2 distinct signatures, which usually appear
in the same samples. For detailed comments, see http://cancer.sanger.ac.uk/cosmic/signatures.
38 Recovering these signatures is not surprising as we use data from these references.
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substantial number of samples (389), which appears to be a contributing factor to
the extraction of a super-dominant signature for this cancer type, albeit not the
leading factor – without “de-noising” this signature is not as dominant, nor was it
found in [Fujimoto et al, 2016], where most of the liver cancer samples are published.
We need as much data as possible to study out-of-sample stability in any meaningful
fashion. The (still embargoed) ICGC data appears to hold promise in this regard.
•What about individual cancer types? We ran our NMF analysis on the data
aggregated by cancer type. Can we do the same for individual cancer types? The
answer is yes – after all, this is how NMF is usually applied – but with caveats.
One of the advantages of aggregating the data by cancer type is that it reduces
the noise level. Individual cancer type samples generally are too noisy. Low count
samples exacerbate this issue. Table 7 is an apt testament to this. Once we remove
the “overall” mode (which artificially lowers the value of K), we get too many
factors based on the statistical factor model analysis, and we therefore can expect
a proliferation of signatures as well. As mentioned above, too many signatures
are useless. In fact, high values of K for individual cancer types indicate out-of-
sample instability of any potential signatures. There are methods to reduce noise
for individual cancer types, however, they are outside of the scope hereof and will
be reported elsewhere. A practical motivation for considering individual cancer
types is that within each cancer type there may be biologic factors one may wish to
understand, e.g., mutational spectra of liver cancers can have substantial regional
dependence as they are mutagenized by exposures to different chemicals.39 However,
aggregation by regions within a cancer type may still be warranted to reduce noise.40
• Exome data. The volume of published exome data is substantially higher than
that of the published genome data. In this regard, it would make sense to apply
our methods to the exome data. The caveat is that the exome data is much more
sparsely populated than the genome data, which has the same effect as the low count
samples in the context of the genome data. Aggregation by cancer type is a natural
remedy to this. The main issue is that meticulously ascertaining which samples are
published is time consuming. We plan to discuss the exome data separately.
• “Minimization” and eRank based algorithms. The former typically leads to
lower values of K than the latter. For the data at hand, the eRank based algorithm is
right on the money for fixing the number of signatures. In this regard, it appears that
the eRank based algorithm should be the go-to method, however, the“minimization”
based algorithm is still useful as the two algorithms set the expected range of the
values of K where the search should be performed. Having a (tight) range of K
helps reduce computational cost – as mentioned above, NMF, being an iterative
procedure, is computationally costly. Speaking of which, we observed a reduction of
the number of iterations (within each “sampling” – see above) by about a factor of 10
between the vanilla and “de-noised” matrices. Not only does “de-noising” improve
the quality of the resultant signatures, but it also provides substantial computational
39 We would like to thank Steven Rozen for emphasizing this point to us.
40 Or else expectedly unstable factors in individual cancer types appear too copious (Table 7).
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cost savings. This is not surprising in retrospect. “De-noising” (not aggregation by
cancer type) is the key factor in improving the overall stability – the signatures
based on aggregated data without “de-noising” have much larger error bars.
• Framework. This paper is not intended to be exhaustive in any way. As men-
tioned above, the data we work with here is limited, etc. Rather, the purpose of this
paper is to set forth the framework of factor models for cancer signatures, including
its application as an improvement to NMF. We hope it facilitates further research
and helps identify the (hopefully not too many) underlying cancer signatures.
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A Genome Sample IDs
In this Appendix we give the sample IDs with the corresponding publication refer-
ences for the genome data we use.
 B Cell Lymphoma:
• [Alexandrov et al, 2013b]:
4101316, 4105105, 4108101, 4112512, 4116738, 4119027, 4121361, 4125240, 4133511, 4135350, 4142267, 4158726, 4159170, 4163639,
4175837, 4177856, 4182393, 4189200, 4189998, 4190495, 4193278, 4194218, 4194891.
• [Love et al, 2012]:
G1.
 Bone Cancer:
• [Tirode et al, 2014]:
IC009T, IC015T, IC024T, IC034T, IC044T, IC046T, IC049T, IC053T, IC054T, IC057T, IC058T, IC066T, IC067T, IC071T, IC076T,
IC077T, IC080T, IC082T, IC086T, IC092T, IC093T, IC096T, IC1057T, IC105T, IC106T, IC111T, IC112T, IC114T, IC116T, IC121T,
IC128T, IC130T, IC136T, IC147T, IC149T, IC151T, IC158T, IC165T, IC168T, IC174T, IC193T, IC196T, IC197T, IC198T, IC204T,
IC213T, IC215T, IC224T, IC242T, IC248T, IC254T, IC262T, IC263T, IC264T, IC267T, IC268T, IC270T, IC271T, IC272T, IC273T,
IC274T, IC275T, IC277T, IC278T, IC279T, IC280T, IC282T, IC283T, IC284T, IC286T, IC288T, IC294T, IC295T, IC296T, IC297T,
IC299T, IC300T, IC301T, IC302T, IC303T, IC305T, IC306T, IC309T, IC310T, IC311T, IC315T, IC316T, IC318T, IC319T, IC323T,
IC324T, IC325T, IC340T, IC343T, IC349T, IC831T, IC929T, IC973T.
 Brain Lower Grade Glioma:
• [Alexandrov et al, 2013b]:
PA10, PA102, PA103, PA105, PA107, PA109, PA11, PA110, PA112, PA116, PA117, PA12, PA131, PA134, PA136, PA138, PA14,
PA143, PA145, PA148, PA149, PA157, PA166, PA17, PA20, PA21, PA22, PA25, PA3, PA36, PA4, PA41, PA43, PA46, PA48, PA5,
PA53, PA54, PA55, PA56, PA58, PA59, PA62, PA63, PA64, PA65, PA69, PA70, PA73, PA75, PA79, PA8, PA81, PA82, PA83, PA84,
PA85, PA86, PA87, PA9, PA90, PA93, PA96.
• [Zhang et al, 2013]:
SJLGG001, SJLGG002, SJLGG003, SJLGG004, SJLGG005, SJLGG006, SJLGG006R, SJLGG007, SJLGG008, SJLGG009,
SJLGG010, SJLGG011, SJLGG012, SJLGG013, SJLGG015, SJLGG016, SJLGG018, SJLGG019, SJLGG020, SJLGG021, SJLGG022,
SJLGG024, SJLGG025, SJLGG026, SJLGG027, SJLGG028, SJLGG029, SJLGG030, SJLGG031, SJLGG032, SJLGG033, SJLGG034,
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SJLGG035, SJLGG037, SJLGG038, SJLGG039, SJLGG040, SJLGG042.
 Breast Cancer:
• [Nik-Zainal et al, 2012]:
PD3851a, PD4085a, PD4088a, PD4103a, PD4120a, PD4194a, PD4192a, PD4198a, PD4199a, PD4248a, PD4086a, PD4109a, PD4107a,
PD3890a, PD3905a, PD4005a, PD4006a, PD3904a, PD3945a, PD4115a, PD4116a.
• [Alexandrov et al, 2013b]:
PD3989a, PD4069a, PD4072a, PD4080a, PD4224a, PD4225a, PD4255a, PD4261a, PD4266a, PD4267a, PD4315a, PD4604a, PD4605a,
PD4606a, PD4607a, PD4608a, PD4613a, PD4826a, PD4833a, PD4836a, PD4841a, PD4847a, PD4951a, PD4952a, PD4953a, PD4954a,
PD4955a, PD4957a, PD4958a, PD4959a, PD4962a, PD4963a, PD4965a, PD4966a, PD4967a, PD4968a, PD4970a, PD4971a, PD4972a,
PD4975a, PD4976a, PD4980a, PD4981a, PD4982a, PD4983a, PD4985a, PD4986a, PD5928a, PD5934a, PD5935a, PD5936a, PD5942a,
PD5944a, PD5947a, PD5951a, PD5956a, PD6018a, PD6041a, PD6042a, PD6043a, PD6044a, PD6045a, PD6046a, PD6049a, PD6409a,
PD6410a, PD6411a, PD6413a, PD6417a, PD6418a, PD6422a, PD6466b, PD6719a, PD6720a, PD6721a, PD6722a, PD7199a, PD7201a,
PD7207a, PD7208a, PD7209a, PD7210a, PD7212a, PD7214a, PD7215a, PD7216a, PD7217a, PD7218a, PD7219a, PD7221a, PD7321a,
PD7404a, PD7409a, PD7431a, PD7433a, PD8618a, PD8622a, PD8623a.
 Chronic Lymphocytic Leukemia:
• [Alexandrov et al, 2013b]:
001-0002-03TD, 003-0005-09TD, 012-02-1TD, 004-0012-05TD, 005-0015-01TD, 006-0018-01TD, 007-0020-01TD, 008-0022-01TD, 009-
0026-02TD, 013-0035-01TD, 016-0040-02TD, 017-0042-01TD, 018-0046-01TD, 019-0047-01TD, 020-0049-01TD, 022-0053-01TD, 023-
0056-01TD, 027-0063-01TD, 029-0065-01TD, 030-0066-01TD, 032-0069-01TD, 033-0070-01TD, 038-0087-01TD, 039-0076-01TD, 040-
0088-01TD, 041-0090-01TD, 042-0091-01TD, 043-0094-01TD, 044-0092-01TD, 045-0082-04TD, 048-0089-01TD, 049-0086-01TD, 051-
0099-05TD, 052-0103-01TD, 053-0104-02TD, 054-0114-05TD, 063-0127-01TD, 064-0128-01TD, 082-02-1TD, 083-01-2TD, 090-02-1TD,
091-01-6TD, 100-02-2TD, 110-0218-04TD, 117-01-1TD, 124-01-1TD, 136-02-3TD, 141-02-3TD, 144-01-1TD, 145-01-1TD, 146-01-5TD,
148-02-3TD, 152-01-4TD, 155-01-1TD, 156-01-1TD, 157-01-1TD, 159-01-1TD, 165-01-5TD, 166-01-4TD, 168-02-2TD, 170-01-3TD,
171-01-2TD, 172-01-1TD, 173-01-3TD, 174-01-3TD, 175-01-3TD, 178-01-2TD, 181-01-3TD, 182-01-4TD, 184-01-4TD, 185-01-6TD,
186-01-6TD, 188-01-2TD, 189-01-1TD, 191-01-3TD, 192-01-4TD, 193-01-1TD, 194-01-2TD, 195-01-5TD, 197-01-3TD, 264-01-7TD,
266-01-7TD, 267-01-6TD, 270-01-2TD, 272-01-2TD, 273-01-5TD, 274-01-3TD, 275-01-2TD, 276-01-4TD, 278-01-4TD, 279-01-4TD,
280-01-4TD, 282-01-12TD, 290-1950-01TD, 319-01-1TD, 321-01-1TD, 322-01-1TD, 323-01-1TD, 324-01-1TD, 325-01-1TD, 326-01-
1TD, 328-01-1TD, 375-1099-15TD, 618-1503-04TD, 642-1991-01TD, 680-1992-01TD, 758-2041-01TD, 761-01-1TD, 785-1836-01TD.
• [Puente et al, 2011]:
CLL4-ARTICLE.
• [Puente et al, 2015]:
125, 128, 137, 141, 151, 178, 192, 26, 277, 282, 294, 306, 308, 318, 342, 343, 367, 393, 467, 473, 477, 519, 523, 564.
 Esophageal Cancer:
• [Cheng et al, 2016]:
ESCC-ESCC-001T, ESCC-ESCC-002T, ESCC-ESCC-003T, ESCC-ESCC-004T, ESCC-ESCC-005T, ESCC-ESCC-006T,
ESCC-ESCC-008T, ESCC-ESCC-009T, ESCC-ESCC-010T, ESCC-ESCC-011T, ESCC-ESCC-012T, ESCC-ESCC-013T,
ESCC-ESCC-014T, ESCC-ESCC-015T, ESCC-ESCC-016T, ESCC-ESCC-017T, ESCC-ESCC-018T.
Gastric Cancer:
• [Wang et al, 2014]:
pfg005T, pfg008T, pfg022T, pfg023T, pfg030T, pfg031T, pfg032T, pfg034T, pfg035T, pfg036T, pfg038T, pfg039T, pfg043T, pfg050T,
pfg052T, pfg053T, pfg054T, pfg057T, pfg058T, pfg059T, pfg060T, pfg062T, pfg064T, pfg065T, pfg068T, pfg069T, pfg072T, pfg073T,
pfg076T, pfg081T, pfg082T, pfg088T, pfg089T, pfg092T, pfg094T, pfg097T, pfg099T, pfg100T, pfg102T, pfg103T, pfg104T, pfg105T,
pfg106T, pfg107T, pfg108T, pfg115T, pfg116T, pfg118T, pfg119T, pfg120T, pfg121T, pfg122T, pfg123T, pfg124T, pfg125T, pfg127T,
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pfg129T, pfg130T, pfg132T, pfg135T, pfg136T, pfg138T, pfg142T, pfg143T, pfg144T, pfg145T, pfg146T, pfg151T, pfg156T, pfg157T,
pfg160T, pfg164T, pfg166T, pfg167T, pfg173T, pfg180T, pfg181T, pfg182T, pfg205T, pfg212T, pfg213T, pfg217T, pfg220T, pfg222T,
pfg228T, pfg258T, pfg272T, pfg277T, pfg282T, pfg311T, pfg316T, pfg317T, pfg344T, pfg373T, pfg375T, pfg378T, pfg398T, pfg413T,
pfg416T, pfg424T.
 Liver Cancer:
• [Sung et al, 2012]:
HK101T, HK105T, HK106T, HK108T, HK113T, HK114T, HK115T, HK116T, HK117T, HK11T, HK122T, HK126T, HK131T, HK13T,
HK145T, HK14T, HK154T, HK159T, HK169T, HK172T, HK174T, HK177T, HK179T, HK17T, HK180T, HK181T, HK182T, HK186T,
HK193T, HK198T, HK19T, HK200T, HK203T, HK204T, HK205T, HK206T, HK207T, HK21T, HK22T, HK23T, HK260T, HK261T,
HK262T, HK266T, HK267T, HK268T, HK26T, HK272T, HK273T, HK274T, HK276T, HK29T, HK30T, HK32T, HK34T, HK35T,
HK36T, HK38T, HK39T, HK41T, HK43T, HK45T, HK46T, HK49T, HK53T, HK55T, HK58T, HK60T, HK62T, HK63T, HK64T,
HK65T, HK67T, HK68T, HK70T, HK71T, HK73T, HK75T, HK76T, HK79T, HK81T, HK82T, HK84T, HK87T, HK90T, HK92T,
HK95T, HK98T.
• [Fujimoto et al, 2016]:
RK001 C01, RK002 C, RK003 C, RK004 C01, RK005 C, RK006 C1, RK006 C2, RK007 C01, RK010 C, RK012 C01, RK014 C01,
RK015 C, RK016 C01, RK018 C01, RK019 C, RK020 C01, RK021 C01, RK022 C01, RK023 C, RK024 C, RK025 C, RK026 C01,
RK027 C01, RK028 C01, RK029 C, RK030 C01, RK031 C01, RK032 C01, RK033 C01, RK034 C, RK035 C01, RK036 C01,
RK037 C01, RK038 C01, RK040 C01, RK041 C01, RK042 C, RK043 C01, RK044 C01, RK046 C01, RK046 C02, RK047 C01,
RK048 C, RK049 C01, RK050 C, RK051 C01, RK052 C01, RK053 C01, RK054 C01, RK055 C01, RK056 C01, RK057 C01,
RK058 C01, RK059 C01, RK060 C01, RK061 C01, RK062 C01, RK063 C, RK064 C01, RK065 C01, RK066 C01, RK067 C01,
RK068 C, RK069 C01, RK070 C01, RK071 C01, RK072 C01, RK073 C01, RK074 C01, RK075 C01, RK076 C01, RK077 C01,
RK079 C01, RK080 C01, RK081 C01, RK082 C01, RK083 C01, RK084 C01, RK085 C01, RK086 C01, RK087 C01, RK088 C01,
RK089 C01, RK090 C01, RK091 C01, RK092 C01, RK093 C01, RK095 C01, RK096 C01, RK098 C01, RK099 C01, RK100 C01,
RK101 C01, RK102 C01, RK103 C01, RK104 C01, RK105 C01, RK106 C01, RK107 C01, RK108 C01, RK109 C01, RK110 C01,
RK111 C01, RK112 C01, RK113 C01, RK115 C01, RK116 C01, RK117 C01, RK118 C01, RK119 C01, RK120 C01, RK121 C01,
RK122 C01, RK123 C01, RK124 C01, RK125 C01, RK126 C01, RK128 C01, RK130 C01, RK131 C01, RK133 C01, RK134 C01,
RK135 C01, RK136 C01, RK137 C01, RK138 C01, RK139 C01, RK140 C01, RK141 C01, RK142 C01, RK143 C01, RK144 C01,
RK145 C01, RK146 C01, RK147 C01, RK148 C01, RK149 C01, RK150 C01, RK151 C01, RK152 C01, RK153 C01, RK154 C01,
RK155 C01, RK156 C01, RK157 C01, RK159 C01, RK162 C01, RK163 C01, RK164 C01, RK165 C01, RK166 C01, RK167 C01,
RK169 C01, RK170 C01, RK171 C01, RK172 C01, RK175 C01, RK176 C01, RK177 C01, RK178 C01, RK179 C01, RK180 C01,
RK180 C02, RK181 C01, RK182 C01, RK183 C01, RK184 C01, RK185 C01, RK186 C01, RK187 C01, RK188 C01, RK189 C01,
RK190 C01, RK191 C01, RK193 C01, RK194 C01, RK195 C01, RK196 C01, RK197 C01, RK198 C01, RK199 C01, RK200 C01,
RK201 C01, RK202 C01, RK204 C02, RK205 C01, RK206 C01, RK207 C01, RK208 C01, RK209 C01, RK210 C01, RK211 C01,
RK212 C01, RK213 C01, RK214 C01, RK215 C01, RK216 C01, RK217 C01, RK219 C01, RK220 C01, RK221 C01, RK222 C01,
RK223 C01, RK224 C01, RK225 C01, RK226 C01, RK227 C01, RK228 C01, RK229 C01, RK230 C01, RK232 C01, RK233 C01,
RK233 C02, RK234 C01, RK235 C01, RK236 C01, RK237 C01, RK240 C01, RK241 C01, RK243 C01, RK244 C01, RK245 C01,
RK254 C01, RK256 C01, RK257 C01, RK258 C01, RK259 C01, RK260 C01, RK261 C01, RK261 C02, RK262 C01, RK263 C01,
RK264 C01, RK265 C01, RK266 C01, RK267 C01, RK268 C01, RK269 C01, RK270 C01, RK272 C01, RK275 C01, RK277 C01,
RK278 C01, RK279 C01, RK280 C01, RK281 C01, RK282 C01, RK283 C01, RK284 C01, RK285 C01, RK287 C01, RK288 C01,
RK289 C01, RK290 C01, RK297 C01, RK298 C01, RK303 C01, RK304 C01, RK305 C01, RK306 C01, RK307 C01, RK308 C01,
RK309 C01, RK310 C01, RK312 C01, RK316 C01, RK317 C01, RK326 C01, RK337 C01, RK338 C01, HX10T, HX11T, HX12T,
HX13T, HX14T, HX15T, HX16T, HX17T, HX18T, HX19T, HX20T, HX21T, HX22T, HX23T, HX24T, HX25T, HX26T, HX27T,
HX28T, HX29T, HX30T, HX31T, HX32T, HX33T, HX34T, HX35T, HX36T, HX37T, HX4T, HX5T, HX9T.
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 Lung Cancer:
• [Imielinksi et al, 2012]:
LU-A08-43, LUAD-2GUGK, LUAD-5V8LT, LUAD-AEIUF, LUAD-D02326, LUAD-E00934, LUAD-E01014, LUAD-E01278, LUAD-
E01317, LUAD-FH5PJ, LUAD-QY22Z, LUAD-S00488, LUAD-S01302, LUAD-S01331, LUAD-S01341, LUAD-S01345, LUAD-S01346,
LUAD-S01356, LUAD-S01381, LUAD-S01404, LUAD-S01405, LUAD-S01467, LUAD-S01478, LUAD-U6SJ7.
 Medulloblastoma:
• [Jones et al, 2012]:
LFS MB1, LFS MB2, LFS MB4, MB1, MB101, MB102, MB104, MB106, MB107, MB108, MB110, MB112, MB113, MB114, MB115,
MB117, MB119, MB12, MB121, MB122, MB124, MB125, MB126, MB127, MB128, MB129, MB130, MB131, MB132, MB134, MB139,
MB15, MB16, MB17, MB18, MB19, MB2, MB20, MB21, MB23, MB24, MB26, MB28, MB3, MB31, MB32, MB34, MB35, MB36,
MB37, MB38, MB39, MB40, MB45, MB46, MB49, MB5, MB50, MB51, MB518, MB53, MB56, MB57, MB58, MB59, MB6, MB60,
MB61, MB612, MB63, MB64, MB66, MB67, MB69, MB7, MB70, MB74, MB75, MB77, MB78, MB79, MB8, MB800, MB81, MB82,
MB83, MB84, MB85, MB86, MB88, MB89, MB9, MB90, MB91, MB92, MB94, MB95, MB96, MB98, MB99.
 Ovarian Cancer:
• [Patch et al, 2015]:
AOCS-001-1, AOCS-004-1, AOCS-005-1, AOCS-034-1, AOCS-055-1, AOCS-056-1, AOCS-057-1, AOCS-058-1, AOCS-059-1, AOCS-
060-1, AOCS-061-1, AOCS-063-1, AOCS-064-1, AOCS-065-1, AOCS-075-1, AOCS-076-1, AOCS-077-1, AOCS-078-1, AOCS-079-1,
AOCS-080-1, AOCS-081-1, AOCS-083-1, AOCS-084-1, AOCS-085-1, AOCS-086-1, AOCS-088-1, AOCS-090-1, AOCS-091-1, AOCS-
092-1, AOCS-093-1, AOCS-093-12, AOCS-094-1, AOCS-095-1, AOCS-096-1, AOCS-097-1, AOCS-104-1, AOCS-105-1, AOCS-106-1,
AOCS-107-1, AOCS-108-1, AOCS-109-1, AOCS-111-1, AOCS-112-1, AOCS-113-1, AOCS-114-1, AOCS-115-1, AOCS-116-1, AOCS-
122-1, AOCS-123-1, AOCS-124-1, AOCS-125-1, AOCS-126-1, AOCS-128-1, AOCS-130-1, AOCS-131-1, AOCS-132-1, AOCS-133-1,
AOCS-137-12, AOCS-139-1, AOCS-143-1, AOCS-144-1, AOCS-145-1, AOCS-146-1, AOCS-147-1, AOCS-148-1, AOCS-149-1, AOCS-
152-1, AOCS-153-1, AOCS-157-1, AOCS-158-1, AOCS-159-1, AOCS-160-1, AOCS-161-1, AOCS-162-1, AOCS-163-1, AOCS-164-1,
AOCS-165-1, AOCS-166-1, AOCS-168-1, AOCS-169-1, AOCS-170-1, AOCS-170-12, AOCS-171-1, AOCS-171-12.
 Pancreatic Cancer:
• [Waddell et al, 2015]:
TD ICGC 0002, TD ICGC 0004, TD ICGC 0005, TD ICGC 0006, TD ICGC 0007, TD ICGC 0008, TD ICGC 0009, TD ICGC 0016,
TD ICGC 0025, TD ICGC 0026, TD ICGC 0031, TD ICGC 0032, TD ICGC 0033, TD ICGC 0034, TD ICGC 0035, TD ICGC 0036,
TD ICGC 0037, TD ICGC 0040, TD ICGC 0042, TD ICGC 0051, TD ICGC 0052, TD ICGC 0054, TD ICGC 0055, TD ICGC 0059,
TD ICGC 0061, TD ICGC 0062, TD ICGC 0063, TD ICGC 0066, TD ICGC 0069, TD ICGC 0072, TD ICGC 0075, TD ICGC 0076,
TD ICGC 0077, TD ICGC 0087, TD ICGC 0088, TD ICGC 0089, TD ICGC 0098, TD ICGC 0103, TD ICGC 0105, TD ICGC 0109,
TD ICGC 0114, TD ICGC 0115, TD ICGC 0116, TD ICGC 0118, TD ICGC 0119, TD ICGC 0121, TD ICGC 0131, TD ICGC 0134,
TD ICGC 0135, TD ICGC 0137, TD ICGC 0138, TD ICGC 0139, TD ICGC 0140, TD ICGC 0141, TD ICGC 0143, TD ICGC 0144,
TD ICGC 0146, TD ICGC 0149, TD ICGC 0153, TD ICGC 0154, TD ICGC 0169, TD ICGC 0182, TD ICGC 0185, TD ICGC 0188,
TD ICGC 0199, TD ICGC 0201, TD ICGC 0205, TD ICGC 0206, TD ICGC 0207, TD ICGC 0212, TD ICGC 0214, TD ICGC 0215,
TD ICGC 0223, TD ICGC 0235, TD ICGC 0239, TD ICGC 0242, TD ICGC 0255, TD ICGC 0257, TD ICGC 0283, TD ICGC 0285,
TD ICGC 0289, TD ICGC 0290, TD ICGC 0295, TD ICGC 0296, TD ICGC 0300, TD ICGC 0303, TD ICGC 0304, TD ICGC 0309,
TD ICGC 0312, TD ICGC 0315, TD ICGC 0321, TD ICGC 0326, TD ICGC 0327, TD ICGC 0328, TD ICGC 0329, TD ICGC 0338,
TD ICGC 0420, TD ICGC 0532, TD ICGC 0548, TD ICGC 0549.
 Prostate Cancer:
• [Gundem et al, 2015]:
A10E-0015 CRUK PC 0015 T1,
A22C-0016 CRUK PC 0016 T1,
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A29C-0017 CRUK PC 0017 T1,
A31C-0018 CRUK PC 0018 T1,
A32C-0019 CRUK PC 0019 T1.
 Renal Cell Carcinoma:
• [Scelo et al, 2014]:
C0001T, C0002T, C0004T, C0005T, C0006T, C0007T, C0008T, C0009T, C0010T, C0011T, C0012T, C0013T, C0014T, C0015T,
C0016T, C0017T, C0018T, C0019T, C0020T, C0021T, C0022T, C0023T, C0024T, C0025T, C0026T, C0027T, C0028T, C0029T,
C0030T, C0031T, C0032T, C0033T, C0034T, C0035T, C0036T, C0037T, C0038T, C0039T, C0040T, C0041T, C0042T, C0043T,
C0044T, C0045T, C0046T, C0047T, C0048T, C0049T, C0050T, C0051T, C0052T, C0053T, C0054T, C0055T, C0056T, C0057T,
C0058T, C0059T, C0060T, C0061T, C0062T, C0063T, C0064T, C0065T, C0066T, C0067T, C0068T, C0069T, C0070T, C0071T,
C0072T, C0073T, C0074T, C0075T, C0076T, C0077T, C0078T, C0079T, C0080T, C0081T, C0082T, C0083T, C0084T, C0085T,
C0086T, C0089T, C0091T, C0092T, C0094T, C0096T, C0097T, C0098T, C0099T, C0100T.
B R Source Code
In this appendix we give the R (R Package for Statistical Computing, http://www.r-
project.org) source code for building purely statistical factor models (using principal
components) based on the algorithm we discuss in Sections 3.2 and 4, including the
“minimization” and eRank based algorithms for fixing the number of factors K in
Section 4. The two functions below are self-explanatory and straightforward as they
follow the formulas therein. This source code is an adaptation of that in Appendix A
of [Kakushadze and Yu, 2016b] reflecting peculiarities in the mutation count data.41
The function bio.cov.pc(ret, use.cor = T, excl.first = F) corresponds to
the “minimization” based method for fixing K. The input is: i) ret, an N×d matrix
Ris (see Section 5), where N is the number of mutation types, and d is the number
of samples (or, in the case where we aggregate samples by cancer type, the number
of cancer types); ii) use.cor, where for TRUE (default) the factors are computed
based on the principal components of the sample correlation matrix Ψij, whereas
for FALSE they are computed based on the sample covariance matrix Cij; excl.first,
where for TRUE the K ′ based method of Subsection 4.3 is used. The output is a list:
result$pc are the first K principal components of a) Cij for use.cor = F, and b) Ψij
for use.cor = T. For details of the other named list members, which are not needed
for our purposes here, see Appendix A of [Kakushadze and Yu, 2016b]. However,
we keep this output as it will be useful in future research projects.
The second function is bio.erank.pc(ret, use.cor = T, do.trunc = F, k = 0,
excl.first = F) and corresponds to the eRank based method for fixing K for the
default parameter k = 0. The input is the same as in the bio.cov.pc() function
except for the additional parameters do.trunc = F and k = 0. For a positive integer
k the code simply takes its value as the number of factors K. For k = 0 (default) the
code uses the eRank method: if do.trunc = F (default), then K = Round(eRank(·)),
41 E.g., we can have cases with vanishing serial variance, and the code deals with this accordingly.
In financial applications this would correspond to a stock that does not trade at all.
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while if do.trunc = T, then K = floor(eRank(·)). (The argument of eRank(·) is the
matrix Cij if use.cor = F, and the matrix Ψij if use.cor = T). The output is the
same as in the bio.cov.pc() function. We use defaults unless stated otherwise.
The source code we give in this appendix is not written to be “fancy” or opti-
mized for speed or in any other way – e.g, using the functions qrm.calc.eigen()
and qrm.calc.eigen.eff(), as applicable, provided in Appendix B and Appendix
C of [Kakushadze and Yu, 2016b], respectively, instead of the built-in R function
eigen() may speed up the code. The sole purpose of the code herein is to illustrate
the algorithms described in the main text in a simple-to-understand fashion. See
Appendix C for some important legalese.
bio.cov.pc <- function (ret, use.cor = T, excl.first = F)
{
print("Running bio.cov.pc()...")
tr <- apply(ret, 1, sd)
take <- tr == 0
tr[take] <- 1
if(use.cor)
ret <- ret / tr
d <- ncol(ret)
x <- ret
x <- x - rowMeans(x)
x <- x %*% t(x) / (ncol(x) - 1)
tv <- diag(x)
x <- eigen(x)
if(excl.first)
{
k1 <- 2
y1 <- sqrt(x$values[1]) * matrix(x$vectors[, 1], nrow(ret), 1)
x1 <- y1 %*% t(y1)
tv <- tv - diag(x1)
}
else
{
k1 <- 1
x1 <- 0
}
g.prev <- 999
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for(k in k1:(d-1))
{
u <- x$values[k1:k]
v <- x$vectors[, k1:k]
v <- t(sqrt(u) * t(v))
x.f <- v %*% t(v)
x.s <- tv - diag(x.f)
take <- x.s < 1e-10
x.s[take] <- 0
z <- x.s / tv
z <- z[is.finite(z)]
g <- abs(sqrt(min(z)) + sqrt(max(z)) - 1)
if(is.na(g))
break
if(g > g.prev)
break
g.prev <- g
spec.risk <- sqrt(x.s)
if(excl.first)
fac.load <- cbind(y1, v)
else
fac.load <- v
fac.cov <- diag(1, k)
cov.mat <- diag(x.s) + x.f + x1
}
y.s <- 1 / spec.risk^2
v <- fac.load
v1 <- y.s * v
inv.cov <- diag(y.s) - v1 %*%
solve(diag(1, ncol(v)) + t(v)%*% v1) %*% t(v1)
if(use.cor)
{
spec.risk <- tr * spec.risk
fac.load <- tr * fac.load
cov.mat <- tr * t(tr * cov.mat)
inv.cov <- t(inv.cov / tr) / tr
}
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result <- new.env()
result$spec.risk <- spec.risk
result$fac.load <- fac.load
result$fac.cov <- fac.cov
result$cov.mat <- cov.mat
result$inv.cov <- inv.cov
result$pc <- x$vectors[, 1:ncol(fac.load)]
result <- as.list(result)
return(result)
}
bio.erank.pc <- function (ret, use.cor = T, do.trunc = F, k = 0,
excl.first = F)
{
print("Running bio.erank.pc()...")
calc.erank <- function(x, excl.first)
{
take <- x > 0
x <- x[take]
if(excl.first)
x <- x[-1]
p <- x / sum(x)
h <- - sum(p * log(p))
er <- exp(h)
if(excl.first)
er <- er + 1
return(er)
}
if(use.cor)
{
tr <- apply(ret, 1, sd)
take <- tr == 0
tr[take] <- 1
ret <- ret / tr
}
x <- ret
x <- x - rowMeans(x)
x <- x %*% t(x) / (ncol(x) - 1)
tv <- diag(x)
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y <- eigen(x)
if(k == 0)
{
er <- calc.erank(y$values, excl.first)
if(do.trunc)
k <- trunc(er)
else
k <- round(er)
}
k <- min(k, ncol(ret) - 2)
fac.load <- t(t(y$vectors[, 1:k]) * sqrt(y$values[1:k]))
fac.cov <- diag(1, k)
x.f <- fac.load %*% t(fac.load)
x.s <- tv - diag(x.f)
take <- x.s < 1e-10
x.s[take] <- 0
spec.risk <- sqrt(x.s)
cov.mat <- diag(x.s) + x.f
y.s <- 1 / spec.risk^2
v <- fac.load
v1 <- y.s * v
inv.cov <- diag(y.s) - v1 %*% solve(diag(1, k) + t(v) %*% v1) %*% t(v1)
if(use.cor)
{
spec.risk <- tr * spec.risk
fac.load <- tr * fac.load
cov.mat <- tr * t(tr * cov.mat)
inv.cov <- t(inv.cov / tr) / tr
}
result <- new.env()
result$spec.risk <- spec.risk
result$fac.load <- fac.load
result$fac.cov <- fac.cov
result$cov.mat <- cov.mat
result$inv.cov <- inv.cov
result$pc <- y$vectors[, 1:k]
result <- as.list(result)
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return(result)
}
C DISCLAIMERS
Wherever the context so requires, the masculine gender includes the feminine and/or
neuter, and the singular form includes the plural and vice versa. The author of this
paper (“Author”) and his affiliates including without limitation Quantigicr Solu-
tions LLC (“Author’s Affiliates” or “his Affiliates”) make no implied or express
warranties or any other representations whatsoever, including without limitation
implied warranties of merchantability and fitness for a particular purpose, in con-
nection with or with regard to the content of this paper including without limitation
any code or algorithms contained herein (“Content”).
The reader may use the Content solely at his/her/its own risk and the reader
shall have no claims whatsoever against the Author or his Affiliates and the Author
and his Affiliates shall have no liability whatsoever to the reader or any third party
whatsoever for any loss, expense, opportunity cost, damages or any other adverse
effects whatsoever relating to or arising from the use of the Content by the reader
including without any limitation whatsoever: any direct, indirect, incidental, spe-
cial, consequential or any other damages incurred by the reader, however caused
and under any theory of liability; any loss of profit (whether incurred directly or
indirectly), any loss of goodwill or reputation, any loss of data suffered, cost of pro-
curement of substitute goods or services, or any other tangible or intangible loss;
any reliance placed by the reader on the completeness, accuracy or existence of the
Content or any other effect of using the Content; and any and all other adversities
or negative effects the reader might encounter in using the Content irrespective of
whether the Author or his Affiliates is or are or should have been aware of such
adversities or negative effects.
The R code included in Appendix B hereof is part of the copyrighted R code
of Quantigicr Solutions LLC and is provided herein with the express permission of
Quantigicr Solutions LLC. The copyright owner retains all rights, title and interest
in and to its copyrighted source code included in Appendix B hereof and any and
all copyrights therefor.
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Table 1: Summaries of skewness for the mutation occurrence counts aggregated by
cancer type for the 14 cancers in Table 2. G is a 96×14 matrix of the so-aggregated
counts. M = Mean/Median ratio, S = skewness (i.e., µ3/µ
3/2
2 , where µk is the k-th
central moment). T = summary across cancer types, X = summary across mutation
categories. 1st Qu. = 1st Quartile, 3rd Qu. = 3rd Quartile.
Quantity Min 1st Qu. Median Mean 3rd Qu. Max
G, M, T 3.35 9.13 11.6 15.4 18.4 86.0
ln(1 +G), M, T 0.98 1.05 1.07 1.08 1.11 1.21
G, S, T 0.69 1.82 2.40 2.33 3.00 3.32
ln(1 +G), S, T -0.57 -0.24 -0.09 -0.08 0.06 0.53
G, M, X 1.06 1.14 1.33 1.39 1.47 2.21
ln(1 +G), M, X 0.97 0.98 0.99 0.99 1.00 1.04
G, S, X 0.69 1.44 2.48 2.37 3.07 4.45
ln(1 +G), S, X -0.76 -0.67 -0.22 -0.15 0.17 0.85
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Table 2: Genome data summary. All Brain Lower Glioma samples are Pilocytic
Astrocytoma samples. See Subsection 6.1 for the data source definitions.
Cancer Type Total Counts # of Samples Source
B Cell Lymphoma 43626 24 A1-2
Bone Cancer 36374 98 B1
Brain Lower Grade Glioma 3572 101 A1, C1
Breast Cancer 254381 119 A1, D1
Chronic Lymphocytic Leukemia 19489 134 A1, E1-2
Esophageal Cancer 1064 17 F1
Gastric Cancer 1996615 100 G1
Liver Cancer 3017487 389 H1-2
Lung Cancer 449527 24 I1
Medulloblastoma 44689 100 J1
Ovarian Cancer 668918 84 K1
Pancreatic Cancer 5087 100 L1
Prostate Cancer 29142 5 M1
Renal Cell Carcinoma 483329 94 N1
All Cancer Types 7053300 1389 Above
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Table 3: Statistical factor counts for the genome data. d = number of samples. M1
= eRank based method; M2 = eRank + K ′ based method; M3 = “minimization”
based method; M4 “minimization” + K ′ based method. See Subsections (4.1), (4.2)
and (4.3) for details. In the eRank based methods we take Round(·) in (21). The
“All Cancer Types” entry is based on the samples for all 14 cancer types in Table 2.
The “Aggregated by Cancer Type” entry corresponds to aggregating the occurrence
counts for all samples within each of the 14 cancer types in this table and running
the aforementioned algorithms for fixing K on the resulting 96× 14 matrix.
Cancer Type d K (M1) K (M2) K (M3) K (M4)
B Cell Lymphoma 24 5 18 5 11
Bone Cancer 98 14 54 16 33
Brain Lower Grade Glioma 101 37 51 23 30
Breast Cancer 119 6 37 6 22
Chronic Lymphocytic Leukemia 134 3 43 4 23
Esophageal Cancer 17 12 13 8 8
Gastric Cancer 100 3 12 1 9
Liver Cancer 389 2 38 1 20
Lung Cancer 24 2 9 1 7
Medulloblastoma 100 11 52 10 33
Ovarian Cancer 84 3 21 2 13
Pancreatic Cancer 100 36 52 23 33
Prostate Cancer 5 2 3 2 3
Renal Cell Carcinoma 94 3 23 2 17
All Cancer Types 1389 2 15 1 18
Aggregated by Cancer Type 14 1 7 1 5
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Table 4: Average pair-wise correlation (Avg.Cor, in the units of 1%) and the first
5 eigenvalues (Eig.1-5) of the sample correlation matrix based on the genome data.
(For Prostate Cancer the fifth eigenvalue is null as d = 5.)
Cancer Type Avg.Cor Eig.1 Eig.2 Eig.3 Eig.4 Eig.5
B Cell Lymphoma 66.6 65.0 5.67 3.08 2.54 2.23
Bone Cancer 48.1 48.1 3.31 2.03 1.88 1.81
Brain Lower Grade Glioma 17.7 20.3 4.52 3.91 3.47 3.23
Breast Cancer 65.2 64.1 6.18 3.01 2.07 1.11
Chronic Lymphocytic Leukemia 79.6 77.6 1.73 1.23 1.17 1.07
Esophageal Cancer 16.7 23.3 9.58 7.59 7.34 6.98
Gastric Cancer 80.9 78.2 6.41 3.95 1.62 0.68
Liver Cancer 87.9 84.7 1.77 1.09 0.90 0.76
Lung Cancer 80.0 78.3 6.03 4.47 1.93 1.17
Medulloblastoma 54.2 53.6 3.33 2.01 1.76 1.63
Ovarian Cancer 75.6 73.8 6.04 2.64 1.99 1.31
Pancreatic Cancer 17.0 21.3 5.38 3.71 3.27 2.84
Prostate Cancer 68.1 68.5 11.5 8.60 7.43 0
Renal Cell Carcinoma 78.2 75.9 5.89 1.86 1.63 0.97
All Cancer Types 88.1 84.9 5.47 0.77 0.58 0.37
Aggregated by Cancer Type 96.1 92.4 1.26 0.89 0.51 0.34
Table 5: Summaries of the absolute values of pair-wise inner products (in the units
of 1%) between the a-th principal components (PCs), a = 1, 2, 3, and also for a
combination of the 2nd and 3rd PCs, of the sample correlation matrices [Ψ(α)]ij for
the 14 individual cancer types in Table 3. 1st Qu. = 1st Quartile, 3rd Qu. = 3rd
Quartile, StDev = standard deviation, MAD = mean absolute deviation.
prin.comp Min 1st Qu. Median Mean 3rd Qu. Max StDev MAD
1st 77.82 90.17 97.93 94.45 99.12 99.72 6.205 2.304
2nd 0.171 6.035 14.72 20.08 29.94 69.35 17.63 14.14
3rd 0.160 4.855 10.60 15.76 21.98 71.63 15.90 11.01
2nd+3rd 0.160 5.190 12.40 17.96 24.28 82.30 17.31 12.01
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Table 6: Cross-sectional summaries of |√NV (1)i −1| (in the units of 1%), where V (1)i
is the first principal component of the sample covariance matrix Ψij for: each of the
14 cancer types; all cancer types; and data aggregated by cancer type (see Table 3).
Cancer Type Min 1st Qu. Median Mean 3rd Qu. Max
B Cell Lymphoma 0.169 3.102 6.030 7.777 9.975 44.02
Bone Cancer 0.402 7.227 12.61 14.57 19.18 48.52
Brain Lower Grade Glioma 0.208 10.26 24.91 28.82 41.19 105.6
Breast Cancer 0.093 3.653 6.898 9.521 10.91 47.82
Chronic Lymph. Leukemia 0.026 3.196 5.242 7.232 7.128 54.85
Esophageal Cancer 0.092 19.17 42.68 47.30 65.43 138.7
Gastric Cancer 0.061 2.084 4.586 5.078 6.487 15.95
Liver Cancer 0.033 1.419 2.297 2.954 3.255 19.76
Lung Cancer 0.214 4.399 5.646 8.916 7.841 49.05
Medulloblastoma 0.393 5.862 10.42 12.09 15.90 46.33
Ovarian Cancer 0.040 2.395 4.648 6.792 6.728 53.78
Pancreatic Cancer 0.013 20.64 39.54 40.09 56.66 115.4
Prostate Cancer 0.151 3.871 10.01 13.42 15.49 104.9
Renal Cell Carcinoma 0.168 2.938 5.127 6.250 7.046 42.73
All Cancer Types 0.043 1.442 2.552 3.461 4.024 17.58
Aggr. by Cancer Type 0.048 0.565 1.059 1.232 1.383 6.576
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Table 7: Statistical factor counts for the genome data with the “overall” mode
factored out – see Subsection 6.2.3. The notations are the same as in Table 3.
Cancer Type d K (M1) K (M2) K (M3) K (M4)
B Cell Lymphoma 24 17 19 11 13
Bone Cancer 98 49 56 28 32
Brain Lower Grade Glioma 101 43 51 24 34
Breast Cancer 119 35 42 18 30
Chronic Lymphocytic Leukemia 134 26 50 15 37
Esophageal Cancer 17 12 13 7 8
Gastric Cancer 100 12 16 7 14
Liver Cancer 389 36 44 24 40
Lung Cancer 24 8 13 4 9
Medulloblastoma 100 46 55 28 32
Ovarian Cancer 84 20 27 12 21
Pancreatic Cancer 100 41 53 23 31
Prostate Cancer 5 3 3 3 3
Renal Cell Carcinoma 94 23 33 13 30
All Cancer Types 1389 21 41 14 32
Aggregated by Cancer Type 14 7 8 5 6
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Table 8: Average pair-wise correlation and the first 5 eigenvalues of the sample
correlation matrix for the genome data with the “overall” mode factored out – see
Subsection 6.2.3. The notations are the same as in Table 4.
Cancer Type Avg.Cor Eig.1 Eig.2 Eig.3 Eig.4 Eig.5
B Cell Lymphoma -0.98 19.9 9.51 6.79 6.15 6.02
Bone Cancer -1.04 11.4 4.32 3.92 3.08 3.02
Brain Lower Grade Glioma -0.01 14.0 4.70 4.20 3.62 3.49
Breast Cancer -0.31 15.5 14.3 5.27 3.51 2.84
Chronic Lymphocytic Leukemia -0.92 31.8 6.13 3.08 2.96 2.58
Esophageal Cancer 0.16 19.3 10.9 9.37 8.65 8.08
Gastric Cancer -0.42 30.8 25.2 7.25 4.02 3.12
Liver Cancer -0.87 15.1 11.3 8.17 5.59 3.81
Lung Cancer -0.44 44.1 13.5 6.74 5.49 4.90
Medulloblastoma -1.04 13.6 4.84 4.00 3.54 2.95
Ovarian Cancer -0.81 22.8 17.3 8.23 4.17 4.05
Pancreatic Cancer -0.01 17.2 4.65 3.98 3.29 3.15
Prostate Cancer -0.67 30.6 24.8 22.6 18.0 0
Renal Cell Carcinoma 0.15 25.6 11.9 7.78 5.05 3.85
All Cancer Types -0.89 32.9 11.7 5.68 4.41 3.23
Aggregated by Cancer Type -0.91 28.9 21.0 15.6 7.94 5.77
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Table 9: Statistical factor counts for the genome data with Ris = Gis (no log – see
Subsection 6.2.4 for details). The notations are the same as in Table 3.
Cancer Type d K (M1) K (M2) K (M3) K (M4)
B Cell Lymphoma 24 3 10 2 6
Bone Cancer 98 11 37 8 20
Brain Lower Grade Glioma 101 34 46 18 27
Breast Cancer 119 5 17 2 11
Chronic Lymphocytic Leukemia 134 4 24 4 14
Esophageal Cancer 17 11 13 8 9
Gastric Cancer 100 4 7 3 4
Liver Cancer 389 3 11 2 7
Lung Cancer 24 2 6 2 5
Medulloblastoma 100 7 38 5 22
Ovarian Cancer 84 4 10 2 5
Pancreatic Cancer 100 25 43 15 30
Prostate Cancer 5 3 3 2 3
Renal Cell Carcinoma 94 4 9 2 5
All Cancer Types 1389 6 10 4 6
Aggregated by Cancer Type 14 2 3 1 3
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Table 10: Average pair-wise correlation and the first 5 eigenvalues of the sample
correlation matrix for the genome data with Ris = Gis (no log – see Subsection 6.2.4
for details). The notations are the same as in Table 4.
Cancer Type Avg.Cor Eig.1 Eig.2 Eig.3 Eig.4 Eig.5
Cell Lymphoma 76.6 75.1 6.67 4.59 2.89 1.75
Bone Cancer 51.1 50.9 6.19 3.33 2.81 2.59
Brain Lower Grade Glioma 17.7 20.5 5.15 4.74 4.31 3.67
Breast Cancer 60.8 62.0 13.4 3.50 2.69 1.09
Chronic Lymphocytic Leukemia 74.3 72.5 4.23 2.20 1.79 1.34
Esophageal Cancer 16.8 25.0 10.9 7.72 7.42 6.65
Gastric Cancer 57.5 57.8 14.3 13.3 2.72 1.87
Liver Cancer 72.9 71.5 10.4 4.08 1.85 1.60
Lung Cancer 79.2 78.5 8.28 4.82 1.09 0.92
Medulloblastoma 63.5 62.3 4.27 2.86 2.29 1.84
Ovarian Cancer 63.9 62.8 15.8 4.63 2.42 1.94
Pancreatic Cancer 20.5 28.5 7.30 4.10 3.75 3.09
Prostate Cancer 65.9 66.7 13.5 9.39 6.44 0
Renal Cell Carcinoma 60.8 60.0 15.4 9.97 2.21 0.97
All Cancer Types 49.2 49.4 15.3 8.92 5.97 3.88
Aggregated by Cancer Type 74.7 73.7 16.9 2.91 1.43 0.75
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Table 11: Statistical factor counts for the genome data with Ris = Gis (no log) with
the “overall” mode factored out – see Subsection 6.2.5 for details. The notations
are the same as in Table 3.
Cancer Type d K (M1) K (M2) K (M3) K (M4)
B Cell Lymphoma 24 3 7 2 6
Bone Cancer 98 19 33 10 21
Brain Lower Grade Glioma 101 29 45 17 33
Breast Cancer 119 2 14 1 9
Chronic Lymphocytic Leukemia 134 9 22 5 14
Esophageal Cancer 17 9 12 6 10
Gastric Cancer 100 4 6 2 5
Liver Cancer 389 3 10 3 6
Lung Cancer 24 3 6 2 6
Medulloblastoma 100 10 34 6 26
Ovarian Cancer 84 5 11 3 7
Pancreatic Cancer 100 6 38 5 23
Prostate Cancer 5 3 3 2 3
Renal Cell Carcinoma 94 4 6 2 3
All Cancer Types 1389 7 9 5 6
Aggregated by Cancer Type 14 3 3 2 3
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Table 12: Average pair-wise correlation and the first 5 eigenvalues of the sample
correlation matrix for the genome data with Ris = Gis (no log) with the “overall”
mode factored out – see Subsection 6.2.5 for details. The notations are the same as
in Table 4.
Cancer Type Avg.Cor Eig.1 Eig.2 Eig.3 Eig.4 Eig.5
B Cell Lymphoma 17.6 63.4 16.6 4.87 3.32 1.96
Bone Cancer 2.01 32.1 10.9 4.87 4.56 3.76
Brain Lower Grade Glioma 4.56 25.2 5.27 4.32 3.69 3.60
Breast Cancer 58.1 87.2 3.07 1.32 0.98 0.57
Chronic Lymphocytic Leukemia 1.00 47.3 9.59 4.27 3.70 3.31
Esophageal Cancer 7.75 33.6 12.1 7.90 7.03 6.19
Gastric Cancer 14.1 59.2 20.6 5.32 3.07 2.02
Liver Cancer 8.01 69.5 11.4 3.74 2.86 1.53
Lung Cancer 18.4 70.9 12.2 5.79 1.98 1.41
Medulloblastoma 8.37 50.6 7.63 3.29 3.14 2.56
Ovarian Cancer 7.54 56.4 15.9 7.69 3.77 2.12
Pancreatic Cancer 25.6 64.6 3.24 2.59 2.01 1.78
Prostate Cancer 1.60 44.7 22.7 18.0 10.7 0
Renal Cell Carcinoma 19.0 54.6 23.6 10.2 2.00 0.76
All Cancer Types 3.79 34.8 21.9 11.2 8.54 4.42
Aggregated by Cancer Type 0.75 53.0 33.0 5.77 2.23 1.35
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Table 13: Weights “sig?” and errors “err?” (in the units of 1%, rounded to 2 digits)
for the first 48 mutation categories for the 7 signatures we extract based on the
“de-noised” matrix G˜. See Subsection 7.3 for details.
Mutation sig1 sig2 sig3 sig4 sig5 sig6 sig7 err1 err2 err3 err4 err5 err6 err7
C > A: ACA 0.39 0.7 4.31 0.8 1.72 1.75 1.81 0.18 0.22 0.21 0.17 0.03 0.27 0.25
C > A: ACC 0.49 0.49 2.51 0.5 0.48 1.03 1.61 0.13 0.15 0.12 0.13 0.02 0.14 0.31
C > A: ACG 0.21 0.2 0.9 0 1.75 0.02 0.09 0.06 0.06 0.08 0 0.02 0.04 0.14
C > A: ACT 0.2 0.9 2.77 0.48 1.14 0.74 1.47 0.12 0.16 0.14 0.13 0.02 0.19 0.24
C > A: CCA 0.98 0.83 5.39 0.68 0.27 0.87 0.73 0.29 0.32 0.29 0.12 0.03 0.44 0.28
C > A: CCC 0.7 0.46 4.65 0.55 0.86 0.47 0.47 0.26 0.29 0.28 0.1 0.03 0.4 0.26
C > A: CCG 0.69 0.34 1.17 0 0.29 0 0.23 0.06 0.09 0.11 0.01 0.02 0.01 0.2
C > A: CCT 1.64 0.48 4.53 1.97 0.01 0.66 0.41 0.27 0.29 0.28 0.14 0.02 0.4 0.25
C > A: GCA 0.57 0.99 2.97 1.17 1.42 0.31 1.46 0.13 0.21 0.18 0.09 0.03 0.23 0.35
C > A: GCC 0.54 0.51 2.46 0.31 1.08 0.43 0.56 0.12 0.13 0.14 0.05 0.02 0.18 0.13
C > A: GCG 0.43 0.28 0.9 0 0.6 0 0.07 0.06 0.07 0.08 0 0.01 0.02 0.14
C > A: GCT 0.6 0.74 2.12 1.05 1.14 0.49 0.69 0.1 0.11 0.11 0.04 0.01 0.14 0.16
C > A: TCA 0.69 2.13 3.41 0.97 1.05 1.57 1.27 0.16 0.15 0.08 0.1 0.02 0.18 0.19
C > A: TCC 1.09 1.63 3.37 0.24 4.75 0.86 0.62 0.18 0.18 0.18 0.06 0.05 0.24 0.4
C > A: TCG 0.43 0.31 0.6 0.03 0.39 0.08 0.13 0.03 0.04 0.04 0.02 0.01 0.06 0.09
C > A: TCT 0.94 2.27 3.74 2.21 0.66 1.22 2.4 0.14 0.17 0.15 0.12 0.03 0.22 0.28
C > G: ACA 0.14 0.47 1.12 0.42 1.43 1.14 0.74 0.06 0.06 0.05 0.06 0.02 0.07 0.2
C > G: ACC 0.42 0.51 0.54 0.14 0.21 0.7 0.45 0.02 0.03 0.02 0.02 0.01 0.02 0.08
C > G: ACG 0.08 0.28 0.18 0 0.96 0.13 0.3 0.02 0.02 0.02 0.01 0.01 0.02 0.05
C > G: ACT 0.4 0.91 0.64 0.3 3.1 1.02 0.67 0.03 0.04 0.05 0.03 0.03 0.05 0.08
C > G: CCA 0.61 0.87 0.78 0.1 0.32 0.52 0.31 0.04 0.05 0.03 0.02 0.01 0.05 0.05
C > G: CCC 0.27 0.44 0.7 0.09 0.95 0.62 0.34 0.03 0.04 0.02 0.02 0.01 0.02 0.06
C > G: CCG 0.19 0.03 0.17 0 3 0.02 0.15 0.03 0.04 0.07 0 0.03 0.03 0.1
C > G: CCT 0.56 1.32 0.78 0.16 0.51 0.85 0.54 0.05 0.05 0.06 0.02 0.01 0.04 0.05
C > G: GCA 0.2 0.35 0.61 0.08 1.82 0.35 0.2 0.03 0.02 0.04 0.01 0.02 0.02 0.05
C > G: GCC 0.28 0.47 0.6 0.18 0.4 0.37 0.31 0.02 0.02 0.01 0.01 0 0.02 0.03
C > G: GCG 0.09 0.18 0.2 0 1.8 0.01 0.02 0.02 0.02 0.04 0 0.02 0.01 0.05
C > G: GCT 0.21 0.78 0.47 0.27 1.52 0.51 0.31 0.03 0.03 0.03 0.01 0.02 0.03 0.05
C > G: TCA 0.49 9.4 1.28 0.09 0.38 0.23 0.3 0.46 0.57 0.7 0.12 0.03 0.36 0.48
C > G: TCC 0.47 2.55 0.88 0.16 1.4 0.94 0.34 0.12 0.15 0.15 0.03 0.02 0.09 0.09
C > G: TCG 0.21 0.39 0.17 0 0.32 0.04 0.21 0.01 0.02 0.02 0 0 0.01 0.04
C > G: TCT 0.61 12 1.41 0.53 0.04 1.35 0.84 0.56 0.71 0.89 0.16 0.04 0.42 0.36
C > T: ACA 0.98 0.92 1.46 2.6 0.89 1.83 3.38 0.19 0.23 0.14 0.16 0.04 0.18 0.33
C > T: ACC 2.2 0.57 0.6 0.68 1.58 1.14 1.29 0.09 0.06 0.05 0.08 0.01 0.07 0.15
C > T: ACG 13.7 0.86 0.4 1.49 0.3 1.75 8.25 0.88 0.66 0.38 0.65 0.16 0.6 1.33
C > T: ACT 0.94 0.73 0.9 1.05 2.13 1.48 2.03 0.11 0.13 0.08 0.09 0.01 0.11 0.17
C > T: CCA 1.45 1.3 1.53 0.93 0.76 1.38 2.14 0.08 0.09 0.05 0.09 0.02 0.06 0.08
C > T: CCC 1.2 0.53 1.18 0.88 1.72 1.21 2.28 0.13 0.16 0.1 0.12 0.02 0.11 0.16
C > T: CCG 12.2 1.91 0.34 0.92 0.13 0.67 3.51 0.54 0.36 0.2 0.65 0.12 0.32 1.52
C > T: CCT 0.9 1 1.47 1.03 0.92 1.68 3.44 0.22 0.26 0.15 0.23 0.04 0.17 0.3
C > T: GCA 2.31 0.9 0.78 1.51 1.66 1.34 1.61 0.09 0.06 0.04 0.06 0.01 0.08 0.13
C > T: GCC 2.65 0.52 0.76 1.65 0.29 1.24 1.68 0.12 0.08 0.06 0.09 0.03 0.09 0.22
C > T: GCG 15.2 0.58 0.61 1.88 1 1.57 2.77 0.75 0.44 0.3 0.88 0.15 0.47 1.86
C > T: GCT 1.9 0.66 0.61 1.32 1.64 1.26 2.14 0.13 0.14 0.08 0.07 0.01 0.12 0.09
C > T: TCA 1.62 14.1 1.26 1.42 0.24 1.28 1.93 0.61 0.77 1.04 0.17 0.05 0.46 0.54
C > T: TCC 1.99 3.42 1.05 1.4 1.02 1.96 2.11 0.1 0.12 0.17 0.05 0.02 0.1 0.09
C > T: TCG 7.39 2.9 0.12 0.36 1.76 0.2 2.99 0.32 0.3 0.17 0.37 0.07 0.18 0.99
C > T: TCT 0.94 7.51 1.88 1.86 0.69 1.49 2.09 0.3 0.33 0.47 0.11 0.03 0.22 0.32
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Table 14: Table 13 continued: weights and errors for the next 48 mutation categories.
Mutation sig1 sig2 sig3 sig4 sig5 sig6 sig7 err1 err2 err3 err4 err5 err6 err7
T > A: ATA 0.01 0.03 0.95 0.54 1.2 2.52 0.74 0.02 0.07 0.17 0.08 0.03 0.12 0.37
T > A: ATC 0.32 0.58 0.46 0.53 0.26 0.84 0.7 0.02 0.03 0.03 0.03 0.01 0.03 0.09
T > A: ATG 0.28 0.23 0.93 0.27 1.63 1.9 0.54 0.04 0.06 0.11 0.04 0.02 0.07 0.18
T > A: ATT 0.1 0.52 0.84 1.87 1.07 1.61 1.55 0.08 0.11 0.08 0.09 0.02 0.11 0.34
T > A: CTA 0.22 0.03 1.08 0.02 0.29 2.95 0.03 0.13 0.07 0.23 0.06 0.03 0.29 0.17
T > A: CTC 0.46 0.46 0.87 0.62 1.41 1.45 0.29 0.06 0.05 0.08 0.03 0.02 0.06 0.12
T > A: CTG 0.75 0.45 1.97 0.02 0.27 3.01 0.07 0.2 0.13 0.21 0.06 0.03 0.31 0.25
T > A: CTT 0.43 0.44 1.15 1.28 0.05 1.81 0.73 0.04 0.05 0.09 0.05 0.01 0.05 0.16
T > A: GTA 0.06 0.06 0.76 0.16 1.25 1.34 0.11 0.06 0.05 0.09 0.03 0.02 0.08 0.12
T > A: GTC 0.14 0.21 0.31 0.37 0.88 0.5 0.28 0.01 0.02 0.02 0.01 0.01 0.02 0.06
T > A: GTG 0.25 0.71 1.04 0.24 0.35 0.69 0.24 0.08 0.08 0.04 0.02 0.01 0.1 0.18
T > A: GTT 0.1 0.34 0.55 0.51 1.48 0.65 0.57 0.02 0.03 0.03 0.03 0.01 0.03 0.09
T > A: TTA 0.15 0.22 1.04 1.2 0.4 3.03 1.07 0.07 0.1 0.19 0.08 0.02 0.17 0.5
T > A: TTC 0.23 0.18 0.35 0.26 2.58 1.21 0.35 0.03 0.04 0.08 0.02 0.03 0.07 0.1
T > A: TTG 0.25 0.07 0.73 0.2 0.16 1.94 0.06 0.09 0.07 0.14 0.04 0.02 0.16 0.13
T > A: TTT 0.01 0.33 0.85 1.52 0.37 2.73 1.29 0.04 0.1 0.17 0.09 0.02 0.16 0.47
T > C: ATA 0.19 0.76 1.79 2.07 1.15 2.66 2.92 0.16 0.19 0.14 0.19 0.03 0.13 0.44
T > C: ATC 0.34 0.63 0.37 0.9 0.15 0.71 1.16 0.06 0.07 0.05 0.05 0.01 0.06 0.1
T > C: ATG 0.89 0.93 1.24 1.57 0.56 1.42 1.63 0.05 0.07 0.04 0.05 0.01 0.04 0.08
T > C: ATT 0.22 1.06 0.68 1.35 1.63 1.77 3.22 0.23 0.25 0.15 0.23 0.03 0.22 0.42
T > C: CTA 0.22 0.16 1.02 1.39 0.27 1.1 0.87 0.04 0.06 0.06 0.05 0.01 0.03 0.16
T > C: CTC 0.94 0.41 0.55 1.86 0.42 0.72 0.8 0.04 0.04 0.02 0.06 0.01 0.04 0.08
T > C: CTG 1.26 0.25 0.91 2.29 1.98 0.82 0.54 0.08 0.05 0.07 0.12 0.02 0.04 0.07
T > C: CTT 1.07 0.57 0.88 4.59 0.27 0.76 1.01 0.11 0.1 0.06 0.22 0.04 0.06 0.15
T > C: GTA 0.93 0.13 0.93 1.46 1.53 1.09 0.94 0.06 0.07 0.07 0.03 0.01 0.05 0.15
T > C: GTC 0.4 0.63 0.32 0.99 0.61 0.34 1.08 0.06 0.09 0.05 0.04 0.01 0.06 0.11
T > C: GTG 1.04 0.33 0.64 1.34 1.85 0.59 0.77 0.04 0.03 0.05 0.05 0.01 0.03 0.07
T > C: GTT 0.58 0.41 0.53 1.35 1.58 0.92 1.66 0.1 0.12 0.08 0.07 0.01 0.11 0.17
T > C: TTA 0.21 0.18 0.84 1.41 0.53 1.63 1.64 0.09 0.12 0.1 0.09 0.02 0.1 0.35
T > C: TTC 0.23 0.23 0.34 1.71 1.43 0.98 1.49 0.09 0.12 0.08 0.07 0.01 0.13 0.24
T > C: TTG 0.54 0.54 0.55 0.98 0.27 0.61 0.84 0.03 0.04 0.02 0.02 0.01 0.02 0.05
T > C: TTT 0.38 0.05 0.64 3.03 0.01 3.51 1.64 0.07 0.12 0.24 0.1 0.03 0.17 0.5
T > G: ATA 0 0.27 0.07 0.76 0.72 0.99 0.57 0 0.05 0.05 0.04 0.01 0.08 0.17
T > G: ATC 0.23 0.01 0.05 0.31 1.72 0.52 0.01 0.03 0.03 0.05 0.03 0.02 0.05 0.04
T > G: ATG 0.06 0.37 0.21 0.32 1.22 0.68 0.38 0.02 0.02 0.03 0.02 0.01 0.04 0.07
T > G: ATT 0.19 0.1 0.12 2.19 1.97 1.22 0.32 0.05 0.06 0.08 0.11 0.03 0.09 0.14
T > G: CTA 0 0.34 0.02 0.67 1.02 0.47 0.33 0 0.03 0.02 0.03 0.01 0.05 0.07
T > G: CTC 0.36 0.24 0.02 0.84 2.94 0.3 0.15 0.04 0.04 0.04 0.06 0.03 0.05 0.13
T > G: CTG 0.34 0.5 0.36 0.9 0.46 0.62 0.31 0.02 0.04 0.02 0.04 0.01 0.03 0.06
T > G: CTT 0.82 0.18 0.44 9.96 0.77 0.06 0.05 0.27 0.21 0.12 0.61 0.1 0.14 0.23
T > G: GTA 0 0.17 0.05 0.32 1.57 0.31 0.16 0 0.03 0.03 0.02 0.02 0.04 0.06
T > G: GTC 0.17 0.23 0.07 0.28 0.35 0.21 0.12 0.01 0.02 0.01 0.01 0 0.03 0.04
T > G: GTG 0.06 1.24 0.53 0.3 0.71 0.38 0.34 0.06 0.06 0.07 0.03 0.01 0.08 0.12
T > G: GTT 0.06 0.53 0 3.2 1.61 0.29 0.44 0.06 0.06 0.01 0.17 0.03 0.08 0.09
T > G: TTA 0.02 0.27 0.03 1.04 0.39 1.04 0.89 0.04 0.08 0.04 0.05 0.01 0.11 0.22
T > G: TTC 0.27 0.15 0.1 0.45 1.09 0.84 0.24 0.02 0.03 0.05 0.02 0.01 0.05 0.08
T > G: TTG 0.17 0.57 0.29 0.68 2.15 0.65 0.38 0.05 0.04 0.03 0.03 0.02 0.04 0.12
T > G: TTT 0.69 0.14 0.31 5.45 0.89 2.83 0.78 0.13 0.14 0.19 0.27 0.05 0.19 0.38
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Figure 1: Variability in cross-sectional means. x-axis: the cancer types labeled 1-14
in the order in Table 2. y-axis: the column means of the matrix Ris = ln(1 +Gis).
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Figure 2: Variability in cross-sectional means. x-axis: the cancer types labeled 1-
14 in the order in Table 2. y-axis: exponents of the column means of the matrix
Ris = ln(1 +Gis).
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